



King's Research Portal

DOI:

[10.1038/nrdp.2018.22](https://doi.org/10.1038/nrdp.2018.22)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Meltzer-Brody, S., Howard, L. M., Bergink, V., Vigod, S., Jones, I., Munk-Olsen, T., Honikman, S., & Milgrom, J. (2018). Postpartum psychiatric disorders. *Nature Review Disease Primers*. <https://doi.org/10.1038/nrdp.2018.22>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 Postpartum Psychiatric Disorders

2
3 **Samantha Meltzer-Brody¹, Louise M Howard², Veerle Bergink³, Simone Vigod⁴, Ian Jones⁵,**
4 **Trine Munk-Olsen⁶, Simone Honikman⁷, Jeannette Milgrom⁸**

5
6 ¹ The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

7 ² Kings College, London, United Kingdom

8 ³ Department of Psychiatry and Department of Obstetrics, Gynecology and Reproductive Medicine,
9 Icahn School of Medicine at Mount Sinai, New York

10 ⁴ University of Toronto, Toronto, Canada

11 ⁵ National Centre for Mental Health, MRC Centre for Neuropsychiatric Genetics and Genomics,
12 Division of Psychological Medicine, Cardiff University, Wales, United Kingdom

13 ⁶ Aarhus University, Aarhus, Denmark

14 ⁷ University of Cape Town, Cape Town, South Africa

15 ⁸ Parent-Infant Research Institute and University of Melbourne, Victoria, Australia

16 Correspondance to:

17 S.M-B.

18 samantha_meltzer-brody@med.unc.edu

19
20
21
22 **Abstract** | Pregnancy is a complex and vulnerable period that presents a number of challenges to
23 women, including the development of postpartum psychiatric disorders (PPDs). These disorders
24 can include postpartum depression and anxiety, which are relatively common, and the rare but
25 more severe postpartum psychosis. In addition, other PPDs can include obsessive–compulsive
26 disorder, post-traumatic stress disorder and eating disorders. The aetiology of PPDs is a complex
27 interaction of psychological, social and biological factors, in addition to genetic and environmental
28 factors. The goals of treating postpartum mental illness are reducing maternal symptoms and
29 supporting maternal-child and family functioning. Women and their families should receive
30 psychoeducation about the illness, including evidence-based discussions on risks and benefits of
31 each treatment option. Developing effective strategies in global settings that allow the delivery of
32 targeted therapies to women with different clinical phenotypes and severities of PPD is essential.

33 [H1] Introduction

34 Pregnancy and the first year after childbirth (which collectively can be referred to as the perinatal
35 period) is arguably one of the most transformative times in a woman's life. This timeframe is also a
36 complex and vulnerable period that presents a number of challenges for women. In particular, an
37 increased risk for onset or worsening of psychiatric illness including mood disorders, anxiety
38 disorders and psychosis exists during the first three months postpartum. All types of psychiatric
39 disorders can occur during the postpartum period, with many chronic disorders starting before
40 pregnancy and persisting throughout pregnancy into the postpartum period¹. In this Primer, we
41 focus specifically on the postpartum psychiatric disorders (PPDs). Collectively, the postpartum
42 psychiatric disorders (PPDs) can include postpartum depression, which is relatively common;
43 common anxiety disorders such as generalized anxiety disorder (GAD; which can include anxieties
44 about the health of the baby); post-traumatic stress disorder (PTSD; which can occur due to a
45 traumatic childbirth experience or can reflect pre-existing symptoms due to previous traumas
46 before conception or during pregnancy); and the rarer, but usually severe presentation of
47 postpartum psychosis. Other PPDs include eating disorders (which can worsen or recur
48 postpartum, particularly when the infant is undergoing weaning), and obsessive–compulsive
49 disorder (OCD).

50 In pregnancy, depressive and anxiety disorders are common with recent population estimates of
51 11% for depressive disorders and 15% for anxiety disorders.² Further, antenatal anxiety and
52 depression are one of the greatest risk factors for postpartum psychiatric disorders (PPD).³
53 Inadequate social support and a history of adverse life events increases the risk for PPDs in all
54 countries and levels of society^{4, 5}. However, this risk is increased in poorer socioeconomic
55 populations and lower income countries, due to poverty and limited access to health care.⁶
56 In recent years, awareness of the potentially serious adverse consequences in both the mother
57 and the baby associated with untreated perinatal psychiatric illness has increased. Maternal

suicide due to postpartum mood disorders (including unipolar and bipolar depressive disorders) is a leading cause of maternal mortality.^{7, 8,9} In addition, perinatal mood disorders are associated with an increased risk for low birth weight and premature birth, impaired mother-infant attachment, and infant malnutrition during the first year of life^{10, 11}.

In this Primer, we focus on maternal PPDs, as they are common, morbid, and have a growing literature on the underlying pathophysiology. These disorders should not be confused with the so-called 'baby blues', which are usually described as transient mild mood and anxiety symptoms that often persist ≤ 2 weeks and usually resolve spontaneously with no sequelae.¹² If the symptoms of the 'baby blues' worsen and/or persist, they are considered PPDs. Herein we discuss the epidemiology of PPDs, and their underlying mechanisms and pathophysiology. We mainly focus on maternal PPDs, although paternal disorders are mentioned in some instances (Box 1). Importantly, we review the latest evidence on diagnosis, screening and prevention as well as management of PPDs. Lastly, we hope to put in context the public health impact of these disorders on mothers, their children and families to encourage wide scale adoption of strategies that make maternal mental health a global priority¹³.

[H1] Epidemiology

Data on the incidence of postpartum depression are from studies conducted in countries across the world, and variable incidence and prevalence are reported between countries¹⁴. By comparison, studies estimating the incidence and prevalence of postpartum psychosis are primarily carried out in Europe¹⁵, and demonstrate less variability in reported incidence and prevalence^{16, 17}. Several methodological factors have influenced these differences.¹⁸ For example, particularly for postpartum depression, the definition of the postpartum period is variable between studies, and has been defined as up to 4 weeks, 3 months, 6 months or 12 months postpartum¹⁹. Differences in study designs, such as using different tools to define case-groups and phenotypes can lead to variability in the reported number of cases. Data sources for postpartum depression

and postpartum psychosis include self-reports and interviews, in addition to some population-based register data¹⁶. Moreover, the incomplete availability of longitudinal data that is needed to distinguish between first-time and recurrent psychiatric episodes might impede calculations of the true incidence and prevalence of PPDs. Consequently, a variation in reported incidence and prevalence could be explained by differences in methodologies between studies, which make direct comparisons difficult. In addition, the diverse symptoms of PPDs pose specific challenges to the estimation of prevalence and incidence of these disorders²⁰.

As the literature surrounding the epidemiology of PPDs continues to grow with well-designed studies, we will have a better understanding of if differences in the incidence and prevalence of postpartum depression and postpartum psychosis are due to local/regional and national differences, or if the differences are due to variable study designs and data sources. This knowledge will assist hypothesis generating that might provide clues for the aetiology of these disorders.

[H2] Mood disorders and anxiety

Postpartum depression, comprising major depressive disorder and subthreshold depression, has an estimated point prevalence of 13% in high-income countries¹¹, and ~20% in low-income and middle-income countries, 3 months postpartum (Box 2)²¹. In women with a history of any eating disorder, the prevalence of postpartum depression has been estimated at 35%²². Studies of postpartum depression often rely on self-reported questionnaires, including the commonly used Edinburgh Postnatal Depression Scale (EPDS)^{14, 23}.

Although the prevalence estimates for postpartum mood disorders ranges between studies, guidelines are available that state that these disorders pose substantial public health risks and consequently, must be identified and treated^{24,25}. Moreover, there is consensus that childbirth is a strong and potent risk factor for bipolar disorder. Indeed, the risk of underlying bipolarity in first-

onset depression that occurs in the postpartum period is higher than in first-onset depression that occurs outside the perinatal period. In addition, women with bipolar disorder have a high risk of postpartum episodes, including depression, anxiety, mania and psychosis^{26, 27}.

The estimated prevalence of postpartum anxiety disorders is ~10%, with a prevalence of 6% for GAD²⁸. Anxiety disorders have substantial comorbidity with postpartum depression and other disorders, including postpartum PTSD, eating disorders and the exacerbation of personality disorders¹⁷.

[H2] Postpartum psychosis

The onset of a severe mental disorder requiring acute inpatient psychiatric treatment in the first postpartum months is ~1 per 1,000 births²⁹⁻³², and are considered some of the most severe forms of illness in psychiatry¹⁸. These severe psychiatric disorders that have an onset in the immediate postpartum period are often called postpartum psychosis, which is an umbrella term for disorders recorded as, for example, mania, mixed episodes, psychotic depression, or psychosis not otherwise specified³³. Women with bipolar disorder have the highest risk for postpartum psychosis than women with other psychiatric diagnosis, as the risk for postpartum relapse in women with bipolar disorder is on average 37%¹⁸. However, variations also occur within bipolar disorder, as the risk of a severe episode (ie postpartum psychosis) is greater for women with bipolar I disorder than women with bipolar II disorder³⁴. Additionally, the risk of symptom recurrence is particularly high for women with bipolar disorder who are not receiving medication during pregnancy¹⁸.

Relapse of psychosis can also occur in women with other psychiatric disorders, such as women with schizophrenia, although this is less common³⁵ (~16% within the first 12 months postpartum), and manifests differently from what is observed in women with bipolar disorder¹⁶.

Despite the widespread use of the term postpartum psychosis, this diagnosis is not recognized in current classification systems, including both ICD-10 and DSM-5³⁶. However, it is clear that psychotic episodes are more prevalent during the postpartum period than in other periods in a woman's life, and evidence clearly suggests a particular vulnerability in women with bipolar disorder²⁹.

In women with severe postpartum psychiatric illness, maternal suicide is often a predominate concern. Although maternal suicide is a leading cause of maternal mortality⁷, the rates of completed suicide in postpartum women are lower than those in age-matched women without children³⁷. Nonetheless, the prevention of maternal suicide is paramount and requires careful monitoring during the postpartum period and possibly extending beyond the first year. For example, one study demonstrated that most postpartum suicides occurred between 9 and 12 months postpartum and that the perinatal suicides were by highly lethal means (such as via firearm), suggesting that limiting follow-up to 1, 3 or 6 months postpartum might be insufficient.³⁸

[H1] Mechanisms/pathophysiology

As previously mentioned, childbirth is one of the most potent triggers of psychiatric illness. Given that postpartum mental health disorders are one of the few occurrences in psychiatry whereby a biological trigger occurs at a known time point, elucidating the pathophysiology of these disorders might shed light on the mechanisms of mood and psychiatric disorders more broadly, and is vital for developing new treatment approaches.

The aetiology of all psychiatric disorders, including PPDs, is a complex interaction of psychological, social and biological factors, including the effect of genetic and environmental influences on risk (Figure 1)¹². The involvement of particular combinations of aetiological factors differs between specific PPDs³⁴; for example, biological factors might have a greater role in the triggering of postpartum psychosis, whereas psychosocial factors might have an important contribution in

postpartum depression.³⁴ These are areas of intense investigation and future research is needed to extend our understanding of the many ways that psychological and biological processes interface. Stopping or changing medications in women with a prior history of psychiatric disorders due to concerns about the safety of medication during pregnancy could be considered a simple explanation for the triggering of PPDs. However, continuing medication in pregnancy is protective against mood disorders in a subset of patients³⁹. Similarly, discontinuation of medication does not guarantee that a woman will relapse⁴⁰. However, there is much that is still not understood about PPDs and the onset of PPDs reflects the outcome of many different pathways that manifest in vulnerable women. Future research will need to disentangle the mechanisms of depression in women before, during and after pregnancy to increase our understanding of the similarities and differences between perinatal depression and depression occurring at other times in life. We will next discuss current theories on psychosocial and biological contributions that increase risk for PPDs.

[H2] Psychosocial factors and comorbidities

Psychological and social stressors contribute to the development of maternal PPDs and are associated with poorer outcomes in the infants or children^{41, 42}. In particular, adverse life events and a history of trauma have a greater prevalence in women that develop postpartum mood disorders, compared with mood disorders outside of the perinatal period^{4, 43, 44}. A history of adverse early life experiences can substantially affect a mother's ability to have a strong attachment with her infant⁴⁵, and adverse parent–infant interactions and worse attachment are associated with development of PPDs⁴⁶⁻⁴⁸.

Social support has a vital role in either contributing to or mitigating the impact of postpartum mood disorders on both the mother and child⁴⁹. Indeed, social support, or the degree of tangible support provided from the social network of the mother and from the partner (such as financial support or

assisting with infant care), have the greatest effects on postpartum depression⁵⁰.

Other psychosocial risk factors include a past history of a mood disorder, which is consistently associated with an increased risk of postpartum depression and postpartum psychosis³⁴. In addition, although the strength of the association between risk factors and PPDs is variable between high-income countries and low-income and middle-income countries, one of the strongest psychosocial risk factors in both settings is domestic violence and previous abuse, including abuse during childhood.^{4, 51} Other risk factors with a medium to strong association with PPDs include marital difficulties, migration status and antenatal depression or anxiety^{17, 52}. In addition, poverty, young age (between 14 and 21 years of age), substance misuse, increased parity, multiple births, an unwanted pregnancy, neuroticism, pregnancy complications including obesity and comorbidities (for example diabetes, hypertension and pre-eclampsia) and neonatal problems are associated with PPDs¹⁷.

[H2] Genetic factors

Data from twin and adoption studies have implicated genetic factors in the aetiology of psychiatric disorders outside of the perinatal period, including schizophrenia and mood disorders^{53, 54}.

However, only recently have genetic investigations, primarily of postpartum depression and postpartum psychosis, been conducted.

Genetic epidemiological and linkage studies for postpartum depression have demonstrated the involvement of genetic factors^{55, 56, 57} and two studies have demonstrated the increased heritability of postpartum depression compared with depression outside of the perinatal period^{58, 59}. To date, studies have suggested that episodes of postpartum psychosis are a marker for a more-familial form of bipolar disorder and that the puerperal triggering of bipolar illness is familial.^{60, 61} However, a genome-wide association study (GWAS) for either postpartum depression or postpartum

psychosis using modern genomics methods has not yet been carried out. Future genetic studies of postpartum mood disorders using modern genomics methods will require international collaborations and consortia to include large number of patients; these studies are currently underway^{62, 63}.

Psychological stressors and early life adverse events have a lasting negative impact and can result in pathophysiological changes and altered gene expression due to increased allostatic load (the cumulative stress on the body that is a sum of lifetime exposure to stress)⁶⁴. Potential mechanisms underlying how stressful life events change gene expression include epigenetic modification (such as DNA methylation and histone modification that change DNA accessibility and chromatin structure, subsequently regulating gene expression)⁶⁵, changes in transcriptional control of stress-responsive pathways⁶⁶, and shortened telomere length^{67, 68}. Epigenetic alterations have been reported in two genes, *HP1BP3* and *TTC9B*, which have different methylation patterns in women with postpartum depression, depending on whether the mood symptoms begin during pregnancy and continue into the postpartum period, compared with symptoms that develop postpartum only^{69, 70}. These data indicate that different gene patterns might arise based on the timing of symptom onset. However, given the history of non-replication in many genetic studies, these findings require replication and overall, the mechanism of action in postpartum depression remains to be established.

[H2] Sleep Disruption

An almost universal feature of pregnancy and childbirth is disruption to sleep. In addition, sleep and circadian rhythm disruption can trigger the onset of psychiatric disorders, particularly episodes of mania in the postpartum period^{71, 72}. Thus, that circadian rhythm disruption has not received more attention as a potential mechanism in PPDs is surprising.

Numerous studies have demonstrated profound changes in maternal sleep patterns during the perinatal period. Pregnant women experience poorer subjective sleep quality, increased waking, and more sleep-wake transitions than women who are not pregnant⁷³. In the postpartum period, new mothers have frequent night waking, decreased night-time sleep, increased daytime napping, and a more irregular sleep-wake schedule, which is speculated to increase the risk of PPDs⁷⁴. The mechanisms underlying the reported disrupted maternal sleep patterns in the perinatal period have been reported in two cross-sectional studies. The first study demonstrated a blunted melatonin amplitude is in postpartum women, compared with non-pregnant women,⁷⁵ and the second study demonstrated differences in circadian rhythms between perinatal women with depression and perinatal women without depression; indeed, in the second study, women with depression had clinically-significant circadian rhythm phase shifts.⁷⁴ Further research is needed to better understand the mechanisms of sleep disruption that might trigger PPDs and potential interventions that target the circadian rhythm disruptions during the perinatal period⁷⁶.

[H2] Reproductive Hormones

One important hypothesis for the aetiology of PPDs is based on the temporal onset of these disorders immediately after childbirth, which is a time of major physiological change for women, including alterations in hormonal systems. Multiple lines of evidence have demonstrated that fluctuations in reproductive hormones (such as oestrogen and progesterone) during the perinatal period are substantial contributors to the development of postpartum mood disorders in vulnerable women. Gonadal steroid hormones (such as oestrogen and progesterone) are produced at very high levels during pregnancy, but rapidly decrease to pre-pregnancy levels after childbirth. One study simulated this pattern of hormone expression and demonstrated substantial mood symptoms (such as sadness, anhedonia and anxiety) during the withdrawal period in five of eight women with a history of postpartum depression, but in none of the eight women with no history of postpartum

depression⁷⁷. Thus, women who are vulnerable to postpartum psychiatric episodes might not have gross abnormalities in endocrine physiology (such as no differences in the absolute levels of hormones), but might have an abnormal response to the hormonal fluctuations of pregnancy and childbirth.

Reproductive hormones have important functions in the central nervous system. Oestrogen and progesterone receptors are expressed throughout the brain and can modulate neurotransmission and neuroplasticity via both genomic and non-genomic mechanisms. For example, rodent studies have shown that ovariectomy reduces and estradiol administration increases brain-derived neurotrophic factor (BDNF) levels in the hippocampus and the forebrain⁷⁸; BDNF levels are decreased by stress and depressive symptoms and are increased following treatment with antidepressants⁷⁹. The rapid fall in oestrogen levels in the postpartum period might, therefore, reduce BDNF levels and increase susceptibility to PPDs in women who are vulnerable. Similarly, progesterone has an important role in regulating neurotransmitter synthesis, release and transport⁸⁰ and, has been shown to up-regulate BDNF expression in the hippocampus and cerebral cortex in rodent models⁸¹.

The neurosteroid, allopregnanolone, which is a major metabolite of progesterone, might also have an important role in the aetiology and, potentially, in the treatment of postpartum depression^{82, 83}. Allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABA_A receptors^{84, 85} and animal models have demonstrated that intravenous allopregnanolone administration significantly reduces anxiety and depressive symptoms⁸⁶. Allopregnanolone concentrations reach peak physiological levels during the third trimester of pregnancy and rapidly decrease following childbirth^{87, 88}. The failure of GABA_A receptors to adapt to the rapid fluctuations in allopregnanolone levels [Au:OK?] at childbirth is hypothesized to be a trigger for postpartum depression^{89, 90}. This line of inquiry is being further explored by the development of brexanolone (a proprietary formulation of allopregnanolone) as a treatment for postpartum depression^{91,92}.

Oxytocin is a neuroactive hormone that supports childbirth, lactation, maternal behavior, and social bonding⁹³. Some studies have demonstrated an inverse association between circulating oxytocin levels and postpartum depression⁹⁴ although other studies have not found this⁹⁵. The alterations in the oxytocin system that occur during pregnancy and childbirth do not occur in isolation, and the role of oxytocin in postpartum depression is likely to be complex and not accounted for by absolute levels, similar to the roles of other neuroactive hormones⁸³.

Further, recent neuroimaging data increases our understanding of the neurobiological basis underlying perinatal mood disorders and the development of maternal behavior. Indeed, one study demonstrated that the effects of a polymorphism in *BDNF* (*BDNF* Val⁶⁶Met) on hippocampal function are selectively modulated by estradiol⁹⁶. This work lends further data to the importance of the role of sex steroids on the regulation of behavioural functions associated with psychiatric disorders, such as emotional processing, arousal, cognition, and motivation. Thus, it follows the involvement of sex steroids of brain function could be revealed using neuroimaging. Indeed, multiple cortical and subcortical brain regions have altered activity observed using functional MRI or PET (such as, measurement of brain MAO-A⁹⁷) in mothers with depression, in response to infant and non-infant emotional cues^{98, 99}. These alterations might impact important neuronal networks that are associated with learned reward, reaction to stimuli, stress, motivation and executive functioning. In addition, recent research from functional MRI studies shows distinct neurobiological patterns that distinguish anxiety and depression occurring in the perinatal period, compared with other times of a woman's life, and these patterns might have significant impact on the mother-infant relationship¹⁰⁰.

[H2] Other factors

[H3] Stress axis. The postpartum period is a time of great flux for the HPA stress axis¹⁰¹. Indeed, alterations in the hypothalamic–pituitary–adrenal (HPA) axis occur during pregnancy, such as

corticotropin-releasing hormone (CRH) production by the placenta, resulting in significantly increased levels during pregnancy, which abruptly decline postpartum¹⁰², and rising levels of gonadal steroids that contribute to puerperal hypertrophy of the pituitary and adrenal glands, leading to increases in ACTH and cortisol levels¹⁰³. CRH fluctuations during the perinatal period might trigger HPA axis dysregulation and contribute to the onset of depressive and anxiety symptoms in a subset of vulnerable women¹⁰⁴; however, inconsistent findings have been reported^{105, 106}.

[H3] Thyroid hormones. Thyroid hormones have been implicated in the development of postpartum mood disorders. Thyroid binding globulin (TBG, which transports thyroid hormones in the blood) concentrations increase during pregnancy and might be an index of sensitivity to elevated oestrogen levels. Some data also suggest that decreased TBG levels are a predictor of perinatal depression¹⁰⁷. In addition, first-onset postpartum autoimmune thyroid disorders often co-occur with postpartum mood disorders¹⁰⁸. The occurrence of both disorders coincides with the postpartum rebound phenomena of the maternal immune system, suggesting an overlap in aetiology¹⁰⁹. Supporting this hypothesis, women with increased thyroid peroxidase antibodies during pregnancy have an increased risk for postpartum psychiatric episodes^{109, 110}. Accordingly, the assessment of thyroid function (such as measurement of thyroid-stimulating hormone levels, tri-iodothyronine (T3) and tetraiodothyronine (T4)) is an essential part of diagnostic evaluations in women with postpartum psychiatric episodes.

[H3] Neuroimmune pathways. Neuroimmune pathways might also have a role in the pathophysiology of postpartum mood disorders^{101, 111-113}. The transition from pregnancy into the postpartum period is characterized by an accelerated immune response (mediated through both pro-inflammatory and anti-inflammatory mediators for healing and involution) during labor that

continues into the early postpartum period¹¹⁴. Consequently, immune changes at the end of pregnancy might predict postpartum depression. IL-6 levels are increased in women with postpartum depression compared with postpartum women who do not have depression in some, but not all studies.^{112,115} However, leptin (a protein hormone made by adipose cells that regulates energy and has inflammatory functions), might also be associated with postpartum depression. Indeed, decreased maternal serum leptin levels during delivery are associated with a higher risk for postpartum depression, and might potentially serve as a biomarker for postpartum depression¹¹⁵. Lower levels of Clara cell protein (CC16, an endogenous anti-inflammatory compound) are associated with PPD a few weeks later^{116, 117}. Furthermore, decreased levels of ω 3 polyunsaturated fatty acids (PUFAs) at the end of the third trimester are suggested to associate with increased risk of PPD in the early postpartum period¹¹⁸. The underlying mechanism is hypothesized to be increased peripheral inflammation¹¹⁸ owing to the anti-inflammatory effects of ω 3 PUFAs. In summary, dysregulation of the crosstalk between the immune system and the HPA-stress axis is hypothesized to be associated with the onset of postpartum depression^{101, 119}.

Interestingly, first pregnancies are more often followed by psychiatric episodes than subsequent pregnancies, which may illustrate the dysregulation of psychoneuroimmune systems. This effect is hypothesized to be due to the biological differences between first and subsequent pregnancies, and has raised the possibility of an aetiological link with other medical conditions that have a similar increase in prevalence in first pregnancies such as pre-eclampsia¹²⁰. Intriguingly, pre-eclampsia and postpartum psychosis are both associated with immune dysregulation, for example the increased rates of postpartum autoimmune thyroiditis^{108, 109} and alterations in immune biomarkers (such as, CNS autoantibodies) in women with postpartum psychosis¹²¹. In addition, abnormalities in monocyte and T cell function and tryptophan breakdown has been demonstrated in patients with postpartum psychosis or mania, compared with postpartum women without any psychiatric symptoms.¹²² Patients with postpartum psychosis had monocytosis and failed to demonstrate the physiological T cell increase that is normally observed during the postpartum

period. These findings support the notion that immune system dysregulation contributes to affective instability and severe postpartum episodes¹²².

Future studies are needed to extend our understanding of the ways in which psychological and biological processes interact in PPDs. For example, social support might exert a stress-buffering effect via the downregulation of stress responses, including inflammatory reactivity to stressors and dampened sympathetic and hypothalamic-pituitary-adrenal (HPA) axis activity^{123, 124}.

[H1] Diagnosis, Screening and Prevention

As with all psychiatric disorders, the diagnosis of postpartum depression is reached by a comprehensive clinical interview and diagnostic criteria that provide an operationalised definition of the disorder, using classification systems such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)¹²⁵ or International Classification of Diseases, Tenth Edition (ICD10)¹²⁶. Diagnostic criteria are similar across the DSM-5 and ICD-10, which are the two most common classification systems; however, the DSM-5 uses the term ‘depression with peripartum onset’ to refer to the onset of depression during pregnancy and into the first month postpartum, whereas ICD10 does not use a primary code referring to the perinatal period, although a second code denoting postpartum onset is available (which is not used in practice). However, the diagnosis of psychiatric disorders is more than a list of symptoms and the impact on symptoms of functioning; diagnosis should also include an understanding of predisposing aetiological factors, triggers and maintenance factors, which are elicited by a comprehensive biopsychosocial assessment²⁴.

Postpartum depression is one of the most common postpartum psychiatric disorders, and can be mild and relatively self-limiting lasting only a few weeks, or can be more severe, with severe episodes potentially including psychotic symptoms¹⁷. Some symptoms of depression such as

406 fatigue, sleep disturbance and appetite disturbance need careful enquiry, as a woman with a baby
407 will be more tired than usual and have disrupted sleep (due to the baby needing a feed), although
408 appetite might not be affected as breastfeeding will stimulate appetite despite a low mood.
409 Checking whether the mother is able to sleep when the baby is asleep, whether the fatigue persists
410 after rest and the interest in food will help establish whether the symptoms are pathological and if
411 they are indicative of postpartum depression. Notably, anxiety might be a prominent symptom in
412 postpartum depression⁶³, or can be a symptom of a comorbid anxiety disorder¹²⁷. Diagnostic
413 assessment should evaluate a history of manic or hypomanic symptoms, as first-onset postpartum
414 depression can indicate underlying bipolar disorder²⁶. Diagnostic challenges include barriers to
415 disclosing symptoms due to stigma¹²⁸ and variations in the manifestation of symptoms, which might
416 reflect cultural or educational differences¹²⁹. In addition, it is important to ensure symptoms are not
417 due to an underlying medical condition such as thyroid disease or an early presentation of first
418 episode psychosis.

419 Although postpartum psychosis is not included as a primary diagnosis in the DSM-5 or ICD-10, this
420 disorder is still recognised clinically and is usually considered to be a severe mood disorder.¹⁶
421 Women with postpartum psychosis often have a history of bipolar disorder.¹⁶ Most women have
422 prodromal symptoms before the overt onset of postpartum psychosis; however, some women have
423 acute onset of severe symptoms^{130, 131}. Evaluation of women with postpartum psychosis includes
424 assessment of manic, depressed, anxious and psychotic symptoms, and the assessment of the
425 risk of causing harm to herself or her baby. Women with postpartum psychosis can present with
426 either low or high mood (both elation and irritability), or frequently can present with a mixed state,
427 including symptoms of both mania and depression; a minority of women have an atypical symptom
428 profile with disorientation and/or disturbance of consciousness¹³². Symptoms can also manifest as
429 delusions, hallucinations, and particularly confusion and perplexity and patients can also have
430 severe mood swings, insomnia, agitation and rapid deterioration. Postpartum psychosis is usually
431 a rapid onset severe psychosis, typically starting within the first 2-4 weeks after birth, and is

considered a psychiatric emergency as a lack of self-care and an inability to care for the infant can lead to suicide and/or, in rare cases, infanticide¹⁶. Accordingly, assessment should be carried out quickly (for example, The National Institute for Health and Care Excellence (NICE) recommend assessment within 4 hours of clinical presentation; in clinical practice this means within 24 hours of the acute onset of severe psychiatric symptoms) to ensure the woman can be cared for safely and appropriately. Excluding other medical disorders, such as cerebral space occupying lesions, thyroid disorders or infections is important as part of the diagnostic work-up. In many cases the mother's partner or family ask for psychiatric evaluation when the mother is irritated or agitated and not aware that she is seriously ill.

Anxiety disorders (such as GAD and panic disorder), OCD and PTSD can all manifest in the postpartum period. OCD is characterised obsessive thoughts. Obsessions are intrusive, repetitive thoughts, images or impulses that are unacceptable and/or unwanted and give rise to subjective resistance. By contrast, delusions that occur in psychotic disorders are fixed, false beliefs¹³³ that need appropriate psychological intervention¹⁷. Postpartum OCD poses a particular diagnostic challenge, as intrusive thoughts about harm befalling the infant (such as, what if I drop my infant or I accidentally cut the infant with a knife when I'm cooking) might be perceived as delusional and could lead to concerns about the safety of the infant. However, these thoughts are not associated with actual direct harm and the obsessions remain very ego-dystonic and highly distressing to the patient. Traumatic childbirth experiences can trigger PTSD, particularly in women with prior histories of trauma¹³⁴. Differentiating the exacerbation of PTSD symptoms in women with past trauma and new onset PTSD owing to traumatic childbirth is important¹³⁵. Past trauma history should include assessment of prior childhood abuse, adult interpersonal or other violence, among other forms of trauma. In addition, many women with PTSD or OCD present with symptoms of anxiety and mood symptoms, making the diagnosis of any one particular disorder a challenge^{63, 136}.

Women with a previous history of psychiatric disorders will often experience a worsening of symptoms during the postpartum period, although few studies have examined strategies to mitigate this exacerbation of symptoms³⁹. For women without a prior history of psychiatric disorders, the acute onset of psychiatric symptoms in the postpartum period is often highly distressing. However, whether the first onset of psychiatric symptoms in the postpartum period indicates the beginning of a more persistent and chronic mood disorder, or is a condition that will be restricted only to the postpartum period is unclear. This is an important area for future study.

[H2] Screening

Screening for postpartum depression has attracted widespread interest from researchers, clinicians and policy makers due to the high prevalence and associated sequelae in terms of maternal morbidity and adverse child outcomes. In many countries, screening for postpartum depression during routine obstetrical care, including care by health visitors, is inconsistent, and this strategy has become an area of focus in many countries. In addition, up to 60% of perinatal women with depression do not seek help¹³⁷. However, given the availability of screening instruments and effective treatments¹³⁸, Clinical Practice Guidelines and recommendations are increasingly supportive of routine screening^{139, 140}. More generally, international guidelines reflect a consensus that improved identification of PPDs **[Au:OK?]** is vitally important^{141,142}. Accordingly, several national campaign to increase awareness of PPDs are underway, such as the Maternal Mental Health Alliance¹⁴³ in the UK. This alliance is a coalition of organizations that are dedicated to achieving consistent, accessible and quality mental health care in the first year after giving birth. In addition, state mandates for perinatal depression screening are increasing in the United States, including the US Preventive Services Task Force recommendation¹⁴⁰. However, although this task force has concluded that the evidence base that is sufficient to recommend screening for perinatal

482 depression when combined with adequate support systems^{25, 140} this conclusion has also been
483 criticised by others¹⁴⁴.

484 The most widely researched and used screening tool for postpartum depression is the brief 10-item
485 Edinburgh Postnatal Depression Scale (EPDS¹⁴⁵), which was designed to exclude symptoms that
486 can be normal features of the perinatal period, such as poor sleep, but that are often included in
487 other self-report measures. A cut-off score of 13 is most commonly used to recommend further
488 diagnostic assessment^{146, 147}. In addition, the EPDS includes question about thoughts of self-harm,
489 which can help to mobilise risk assessment and can predict suicidal intent¹⁴⁸. The EPDS has been
490 used prenatally and validated in a number of languages, its properties are relatively well-
491 understood ¹⁴⁷ and it appears to be highly acceptable in the target population ^{149,150}. High EPDS
492 scores can reflect several psychiatric diagnoses. For example, among the 826 screen-positive
493 women out of a sample of 10,000 women, the most common primary diagnosis was unipolar
494 depressive disorder (found in 68.5% of women), but almost two-thirds of women had co-morbid
495 anxiety disorder and 22.6% had a bipolar disorder ¹⁵¹. These data highlight another potential
496 benefit of the EPDS: that most women with a false-negative result for unipolar depression have
497 another diagnosable, and potentially treatable, psychiatric condition.

498 Other generic or perinatal-specific depression measures have been used to identify perinatal
499 depression, but are not as well validated in perinatal women as the EPDS. Other measures include
500 the Postpartum Depression Screening Scale¹⁵², the Beck Depression Inventory-II¹⁵³ and the
501 Patient Health Questionnaire-9^{154,155}. Alternatively, two case finding questions (the so-called
502 Whooley questions ^{141, 156, 157}) can be asked to women to determine whether further mental health
503 assessment should be carried out, and the use of these questions is recommended by NICE
504 guidelines in the United Kingdom. The Whooley questions can also be used to detect any
505 psychiatric disorder, and are not limited to depression².

506 As previously mentioned, postpartum depression are frequently co-morbid with anxiety (in 4.3% of
507 women [Au:OK?]). As anxiety substantially impacts maternal functioning and fetal and infant
508 development^{28, 158 159}, this has spurred efforts to screen for postpartum anxiety. Three sub-items of
509 the EPDS (the so-called EPDS-3A) can be used to identify perinatal anxiety disorders and sub-
510 syndromal anxiety¹⁶⁰. Other screening instruments for anxiety disorders include the Perinatal
511 Anxiety Screening Scale (PASS)¹⁶¹ and the generalized anxiety disorder scale (GAD-7)¹⁶².
512 Screening tools for perinatal OCD and PTSD are also available, such as the specific perinatal OCD
513 screening scale (The POCS),¹⁶³ and a short screening scale for PTSD (SPAN), respectively.¹⁶⁴.

514 The utility of routine screening for postpartum psychosis, hypomanic and manic symptoms and
515 bipolar disorder faces several barriers including a lack of evidence base of effectiveness and the
516 reduced predictive value of screening for a relatively rare condition. Despite steady progress in this
517 area^{165, 166} a consensus test with well-known precision and an agreed cut-off has not been
518 identified^{167,168}. However, the Mood Disorder Questionnaire (MDQ) has shown solid psychometric
519 properties for assessing bipolar disorder and is increasingly used ¹⁶⁹. Taking a full personal and
520 family history might help to identify vulnerability to bipolar disorders which could trigger further
521 diagnostic assessment, given the strong association between bipolar disorder and increased risk
522 for PPDs^{141, 142}.

523 In general, screening programs in the postpartum period should include a clear pathway from
524 screening, to diagnostic assessment and treatment¹⁷⁰. Best practice guidelines agree that all
525 women who have a positive screen need subsequent assessment, during which, co-morbidities
526 and the woman's wider psychosocial context can be explored. Currently, only such well-resourced,
527 integrated management programs have provided evidence that perinatal mental health is improved
528 by depression screening ^{171, 172}. In this regard, e-screening and e-treatments to facilitate integrated,
529 cost-effective care might be useful¹⁷³. Few well-understood, validated screening approaches for
530 PPDs that can ultimately improve morbidity and mortality are available. Indeed, further building of

the evidence-base for screening, including the cost-effectiveness of perinatal depression screening as a policy direction is required^{142, 174}.

[H2] Prevention

Interventions for the prevention of postpartum depression or postpartum anxiety are intended to prevent the onset, duration, or recurrence of these disorders. Prevention can reduce the mental health, physical health and socio-economic burden associated with postpartum depression for mothers, their offspring and families, as well as for health systems. The effectiveness of prevention of postpartum depression is facilitated by the fact that pregnant women are motivated to address factors that will affect their baby¹⁷⁵. The assessment of risk factors for PPDs helps with diagnosis and formulation, but is also important for identifying potentially modifiable targets for prevention and treatment (Box 3)¹⁷⁶. Thus, it is a requirement for both symptom screening and risk assessment that systems exist for adequate follow-up and support. Furthermore, women and clinicians should be informed that the established risk factors might have limited predictive value for individual patients and, therefore, do not guarantee which women will develop or not develop postpartum depression.

Some psychosocial and psychological interventions have reduced the risk of women developing postpartum depression, although no single intervention type or modality appears superior to others. Data from trials included in a Cochrane review¹⁷⁶ as well as randomized controlled trials included in a qualitative review,¹⁷⁵ point towards particularly positive impacts when interventions target at-risk groups (such as women with a previous episode of depression or a recent life stressor), or include interpersonal therapy (IPT). As relationship challenges and lack of social support constitute strong risk factor for PPD, the interpersonal focus of the IPT intervention, therefore aims to address this causative or aggravating factor. Interventions with the most promise include interventions targeting at-risk groups (such as women with a previous episode of

556 depression or a recent life stressor). Trials included in these reviews were conducted among high
557 risk women, based on various factors, as well as women enrolled from the general perinatal
558 population.

559 Trials assessing the use of interpersonal therapy, cognitive behavioural therapy, peer support,
560 parental preparedness, and person-centred approaches for prevention of postpartum depression
561 have demonstrated significantly positive results, whereas trials assessing the use of cognitive
562 behavioural therapy for postpartum depression have demonstrated mixed results. These results,
563 disaggregated for universal, selective or indicated prevention strategies are summarized in a more
564 recent systematic review and meta-analysis¹⁷⁷. The interventions were delivered using several
565 modalities, including home visits and telephone support, provision by professional and lay
566 practitioners, individual and group-based sessions, through multiple contact sessions and at
567 postpartum initiation¹⁷⁶.

568 There is conflicting evidence for the treatment of vulnerable women with antidepressants for the
569 prevention of depressive episodes or anxiety symptoms during the perinatal period as well as
570 anxiety symptoms has conflicting evidence¹⁷⁸. One of the earliest studies demonstrated a
571 reduction in recurrence of postpartum major depression with prophylactic antidepressant treatment
572¹⁷⁹. Small but emerging literature has suggested hormonal therapies, light therapy and other forms
573 of circadian manipulation might be promising therapies for prevention of depression¹⁸⁰. There is no
574 strong evidence for the use of hormonal therapies, acupuncture, supplementation with omega-3
575 polyunsaturated fatty acids, light therapy and other forms of circadian manipulation for prevention
576 of postpartum depression.^{177,180}

577 Interventions for the prevention of postpartum psychosis include careful monitoring for symptom
578 development in women at high risk and adjustments of prophylactic medication, especially in
579 women with bipolar disorder^{18, 24}. Prophylactic treatment during pregnancy might reduce the rate of
580 postpartum relapse in women with bipolar disorder, although no evidence from randomized

controlled trials for this is available. For women with previous postpartum psychosis, prophylactic treatment with lithium or antipsychotics immediately postpartum might reduce relapse¹⁸.

[H1] Management

The goals of treating mental illness in the postpartum period are to reduce maternal psychiatric symptoms and to support maternal-child and family functioning. All women and their families should receive education about the illness and the potential treatment options, including the potential benefits and harms of each treatment option. Social support should be optimized and physical and psychiatric comorbidities should be addressed. In addition, strategies to assist women in obtaining sleep and a stable circadian rhythm are helpful, given that sleep deprivation is common during the postpartum period. In many cases, the symptoms of PPDs influence maternal-child interactions, which should be observed and discussed in a non-judgmental way.

Although specific recommended treatments depend on the underlying diagnosis, in general, a stepped care approach is advocated, in which the intensity of the intervention matches the severity and acuity of the clinical presentation. For example, women with mild symptoms of depressive, anxiety, obsessive-compulsive and/or trauma or stressor-related disorders should first be offered the lowest-intensity interventions such as peer support and guided self-help, whereas women who do not respond to these treatments might require formal psychotherapeutic interventions, such as psychological therapies. For women with severe symptoms, who do not respond to non-pharmacological treatment, or who have bipolar disorder or psychosis, pharmacological interventions are likely to be introduced as a first-line treatment, used alone or in combination with a lower-intensity intervention. In such cases, the well-established benefits of breastfeeding on the infant must be considered in the context of maternal mental wellbeing, the passage of psychotropic medication into breast-milk and the infant, and the potential effects of medications on the neonate. Indeed, when breast-feeding is challenging, and/or when frequent nighttime feedings leads to sleep disruption, symptoms of depression or anxiety might be precipitated or exacerbated. In these

cases, the benefits of breastfeeding must be weighed against the risk of ongoing maternal mental illness, and formula feeding is a viable and often recommended alternative. Other somatic treatments, such as electroconvulsive therapy (ECT), can be considered in women with treatment-refractory disorders. Throughout, monitoring progress to determine when or if to move to a higher-intensity intervention, and to ensure safety for mother and child is important. In the initial assessment and during treatment the patient and her family should be asked if thoughts of suicide or infanticide have occurred. Safety concerns and/or evidence of active psychosis are medical emergencies that require specialist consultation, emergency hospitalization and treatment.

[H2] Mood disorders and anxiety

Treatment of postpartum depression and other non-psychotic mental disorders (such as anxiety, OCD and trauma and stressor-related disorders; **Box 4**) depends on the severity of the initial presentation and the level of functional impairment, including the effect on the maternal–child interaction.¹²⁸ For women with a past history of mental illness, the previous treatment response and the time to response of previous episodes should be considered. The patient's treatment preference, in addition to as access to care and utilization of care should also be considered in all women, as patients who receive their preferred treatment are most likely to benefit from this treatment than other treatments.¹⁸¹ Most women with non-psychotic mental disorders often prefer psychotherapy over pharmacological treatments, although the uptake and effectiveness of this therapy can be limited due to barriers in attending appointments, such as unpredictable infant schedules and competing childcare responsibilities.¹⁸² Similarly, fathers also prefer psychological treatments to pharmacological therapy.¹⁸³ However, some women prefer pharmacological treatment alone, so individualizing treatments based on patient preferences is important. Treating maternal postpartum depression might not always improve the maternal–infant relationship, and additional interventions aimed at the mother–infant dyad or the family as a whole might be required.¹⁸⁴

633

634 **[H3] Psychological Interventions.** Most trials for postpartum depression have focused on non-
635 pharmacological treatments. For women with mild postpartum depression, psychosocial treatments
636 including peer support, guided self-help, and supportive counseling by trained professions such as
637 public health nurses (at home, or in support groups) can improve symptoms. For example, one
638 systematic review of 5 trials demonstrated a 1 year remission rate of 68% in women with
639 postpartum depression who received psychosocial treatments compared with a remission rate of
640 54% in women treated with standard primary care.¹⁸⁵ For women with moderate symptoms of
641 depression, or women who do not responded to psychosocial strategies, psychotherapies such as
642 cognitive-behaviour therapy (CBT) and interpersonal therapy (IPT) that specifically address the
643 psychological and related challenges of transitioning to parenthood are effective when delivered in
644 individual, group, and partner-assisted formats, and either in-person, by telephone, or online.¹⁸⁶ A
645 systematic review of 4 CBT and 1 IPT trials demonstrated a pooled remission rate of 60.3% for
646 these interventions, compared with a rate of 48.1% for usual care.¹⁸⁵

647

648 In addition, a CBT-based program was demonstrated to reduce worry and depressive symptoms in
649 women with postpartum anxiety disorders, including GAD, social phobia and OCD, compared with
650 symptoms at baseline.¹⁸⁷ The effectiveness of CBT for postnatal OCD symptoms was confirmed in
651 a small RCT.¹⁸⁸ Although additional research is required, CBT-based interventions for postpartum
652 anxiety disorders, and specifically interventions such as eye movement desensitization and
653 reprocessing (EMDR) and trauma-focused CBT for trauma and stressor related disorders, can be
654 used, although the latter two interventions have not been specifically evaluated in postpartum
655 women¹⁸⁹.

656 The increasing use of internet-based CBT and the development of mobile apps that use this
657 treatment modality demonstrates the power of digital health, which is often more accessible than

traditional psychotherapy, and extends to individuals who can't participate in psychotherapy. A good example of this is MumMoodBooster, which was developed in Australia¹⁷³.

[H3] Drug therapies. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are the mainstay of pharmacological treatment for postpartum anxiety and depressive disorders. These therapies can be used alone or in combination with psychosocial or psychological treatments. In a systematic review, the pooled remission rate was significantly higher in patients receiving SSRIs (46.0%) compared with those receiving placebo (25.7%).¹⁹⁰ Although pharmacological therapies can be used alone or in combination with psychosocial or psychological treatments, whether combinatorial therapy is superior to either one alone has not been evaluated in postpartum women. However, combinatorial treatment does not lead to further improvements in functional outcomes compared with medication alone, in non-perinatal populations.^{191, 192} To our knowledge, there are no drug treatment trials in maternal anxiety disorders, or in paternal postpartum depression or anxiety. However, SSRI and SNRI medications are first line pharmacological treatments for anxiety and depression outside the postpartum period. The duration of antidepressant therapy required for new-onset postpartum depression, anxiety or a related disorder has not been studied, but clinicians are recommended to follow guidelines for these disorders in the general population. For depression, the initial treatment should be continued for 6 months to 1 year after remission; longer durations are required for severe and/or recurrent illness.¹⁹³

Many women and their partners are concerned about the safety of using antidepressant drugs during breastfeeding. However, the use of antidepressants during the postpartum period is not a contraindication to breastfeeding, and indeed, the avoidance of medication when needed for severe illness is associated with maternal suicides¹⁹⁴. The passage of SSRIs and SNRIs into breast-milk is variable between drugs, but most pass into the breast-milk at <10% of the maternal

dose, which is compatible with breast-feeding.¹⁹⁵ As such, changing the antidepressant drug or the dose during the perinatal period to switch to a drug with lower breast-milk passage is generally not recommended. For new-onset postpartum depression, sertraline is often recommended as a first-line pharmacological treatment due to very minimal passage into breast-milk (Figure 2). However, in patients with a prior history of psychiatric disorders, therapies that have previously demonstrated efficacy should be considered, even those that have less data regarding safety during breastfeeding. Other SSRIs, SNRIs or mirtazapine (an atypical antidepressant) also have minimal passage into breast-milk, so these drugs are unlikely to be a cause for concern. Bupropion is generally not given to lactating women due to case reports of infant seizures associated with exposure to this drug.¹⁹⁶ In cases of severe depression and/or anxiety (with or without psychotic features), older antidepressants, other therapies such as benzodiazepines or antipsychotics might be indicated.

[H3] Other treatments. Given the likely role of hormonal fluctuations in the aetiology of postpartum depression, hormonal treatments have been evaluated. Transdermal oestrogen therapy reduced the symptoms of postpartum depression in one small study, but further trial are required. Progestin therapy worsens postpartum depressive symptoms.¹⁹⁷ One trial of demonstrated the superiority of allopregnenalone to placebo in improving depressive symptoms in 21 women with severe postpartum depression,⁹² although this requires further investigation. Complementary and alternative medicine treatments (for example, folate, s-adenosylmethionine, massage and acupuncture) are not well-supported by evidence.¹⁹⁸ However, using aerobic exercise for postpartum depression was recently examined in a systematic review and has good supporting evidence for mild symptomatology¹⁹⁹. ECT can be considered in severe or treatment-refractory cases of depression.

[H2] Postpartum psychosis

710 Fluctuations in symptoms are common in women with postpartum psychosis, and thoughts of
711 infanticide or suicide are often well hidden. Thus, outpatient treatment is not safe and psychiatric
712 hospitalization is recommended for diagnostic evaluation and treatment ¹⁵. The preferred treatment
713 setting is a mother–baby joint admission unit, but these units are not available worldwide ^{200, 201}.
714 Alternatives are the admission of the mother only to a hospital with expertise in perinatal
715 psychiatric care or women’s mental health, or, if these facilities are unavailable, admission to a
716 standard mental health inpatient setting, or based on a careful assessment of the safety of both the
717 mother and the infant, intensive home treatment where available and with appropriate
718 supervision¹⁶. The effect of these approaches on long term outcomes of the mother and baby are
719 being investigated¹⁵.

720 The management of postpartum psychosis is dependent on psychiatric history. For women with
721 known severe psychiatric illness with non-perinatal episodes, reviewing the nature and
722 effectiveness of past treatments and restarting previous effective treatment is important.
723 Management of women without a history of bipolar disorder or other severe psychiatric disorder are
724 summarized in Figure 2. The main treatment goals for women without a prior history of bipolar
725 disorder, psychosis or other severe psychiatric disorder [Au:OK?] include the limitation of the
726 current episode and the prevention of a bipolar disease course with multiple episodes. Accordingly,
727 management in the first year postpartum should focus on full recovery (that is, complete symptom
728 remission and social and vocational functioning). In the absence of guidelines and controlled trials,
729 treatment recommendations are based on results from naturalistic cohort studies and expert
730 consensus groups^{24, 202}. The largest study (consisting of 68 patients) demonstrated the efficacy of a
731 stepwise sequence of short-term benzodiazepines, antipsychotics and lithium, and showed high
732 remission rates (remission in 98.4% of women) in the acute phase ²⁰³. Moreover, this study
733 demonstrated that lithium monotherapy is protective against relapse of psychosis, depression and
734 mania [Au:OK?] within one year. The second largest study described successful ECT treatment in
735 34 patients with postpartum psychosis of whom many had symptoms of catatonia²⁰⁴. The

effectiveness of lithium and ECT is supported by case reports²⁰⁵. Successful treatment with antipsychotics has been described in case reports^{206, 207}, but antipsychotic monotherapy did not show efficacy in a cohort study²⁰³. Together, lithium monotherapy might be the preferred initial intervention for postpartum psychosis but adjunctive treatment with benzodiazepines or antipsychotics is useful for the acute treatment of agitation, mania and psychotic symptoms, given the well documented effectiveness in non-perinatal populations. Several antipsychotics are used for the treatment of severe PPDs including risperidone, quetiapine and olanzapine²⁰⁸. ECT is the primary treatment for patients with severe catatonic or depressed psychotic features, or if patient's prefer this therapy¹⁵.

Anticonvulsants (that is, antiepileptic medications) are also used less frequently as mood stabilizers in the treatment of bipolar disorder because of concerns of teratogenicity. However, valproate use during pregnancy and lactation is associated with neural tube defects and neurocognitive developmental delays in the offspring^{24, 209}. Thus, valproate use is not advised during the perinatal period, unless the risk/benefit assessment determines a prior efficacy in particular women. By contrast, lamotrigine is used for the treatment of bipolar–depression (not bipolar–mania) and is not associated with an increased risk of congenital malformations in offspring.²¹⁰ A review of recent studies demonstrated that lamotrigine had no adverse outcomes on infant IQ or neurodevelopment.²¹¹

The management of a breastfeeding woman with a severe psychiatric episode is challenging due to concerns about the exposure of breastmilk to pharmacological therapies and the need for sleep preservation in the mother¹⁵. The use of lactation inhibitors should be avoided. In some countries, the mother is recommended to breastfeed only if extensive psychiatric support and access to a pediatric professional that can monitor the infant are available. Moreover, the mother and her partner should be educated about the risks of breastfeeding with pharmacotherapy. In other countries, a more individualized approach (for example, NICE guidelines) based on previous responses to medication, preferences regarding breastfeeding and psychopathology²⁴, other than

avoidance of breastfeeding if lithium (rather than an antipsychotic) is used. Small case series have provided information regarding the safety of lithium in lactation^{212, 213}. When possible, level of lithium in the infants serum should be closely monitored; on average, the serum level of lithium is 25% of the maternal levels, but the range can vary and dehydration can lead to toxic levels^{15,213}. No adverse effects were reported in ten infants of breastfeeding mothers who received ECT²⁰⁴.

[H1] Quality of life

The symptoms and morbidity of postpartum depression are often reported in the academic literature, but this offers only a rather constricted view of the quality of life (QOL) of women with PPDs.^{125,214, 215} Nevertheless, the classic core symptoms of a depressive disorder would be expected to decrease the subjective quality of both an individual's inner life experience (anhedonia, sadness, hopelessness, thoughts of death), and their functioning (psychomotor retardation or agitation, disturbed sleep). Anxiety is frequently co-morbid and this further influences quality of life with persistent worry symptoms.

Definitions vary, but QoL is a broader multidimensional construct which commonly incorporates two central aspects: emotional well-being (including, frequency and intensity of joy, sadness, affection) and life evaluation (how satisfied one is with one's life, for example, housing, employment). Health, and the ability to function, as an essential component of QoL is referred to as health-related quality of life (HRQoL). Maternal QoL during the postpartum period also affects her infant's current and future quality of life. Many mothers with postpartum depression have difficulty interacting with their infants in a positive way²¹⁶, such as making less eye contact, showing less synchronous responsiveness, being uninvolved and showing restricted affect during mother-infant interactions.²¹⁷⁻²¹⁹ Infant attachment security is a key predictor of child outcomes, including neurological, psychological and social outcomes over the course of development²²⁰. In addition, children of mothers with perinatal depression might have poorer psychological outcomes when

787 they reach 18 years of age²²¹. Some women have an intrusive engagement style that might lead to
788 long-term difficulties in child social, cognitive and behavioural domains²²². Women with postpartum
789 psychosis face even more many parenting challenges often including disrupted attachment, which
790 impact on the quality of life for mother and child.²²³

791 One of the most widely used generic measures of QOL is the 36 item short-form (SF-36)^{224, 225},
792 which has eight health domains that measure limitations in physical or usual role activities due to
793 health issues, limitations in usual role or social activities due to emotional issues, pain, mental
794 health, vitality, and general health perceptions. The SF-36 has been used in over 1,000
795 publications and for over 130 disorders including those that occur during the postpartum period,
796 and both the full and short versions of this scale have been validated by numerous studies^{225, 226}.
797 However, few measures of QOL have been developed specifically for use in the postpartum
798 period²²⁷. Only ²²⁸ three instruments for use during the postpartum period were reported in one
799 systematic review: The Mother-Generated Index (MGI)²²⁹, the Maternal Postpartum Quality of Life
800 Questionnaire (MAPP-QOL)²³⁰ and the Rural Postpartum QOL scale (RPQoL)²³¹. The MGI requires
801 women to specify domains of their life that have been affected by the birth of their baby, either
802 positive or negative, and to then score these out of 10. ²³² The most common changes reported
803 were tiredness, less personal time, less time with partner or other family members, a worse
804 relationship with partner or other family members, physical complaints, low self-esteem, financial
805 worries, negative feelings towards the baby, more housework, poor sex life, pleasure from baby, a
806 sense of happiness or fulfilment, contentment as family, high self-esteem and good social life²²⁹.

807 Not surprisingly, people with depressive illness in general report lower scores on generic QoL and
808 HRQoL measures, as do women experiencing postpartum depressed mood. ^{233, 234} Small studies in
809 postpartum women also suggest QoL is amenable to intervention. Improvements in QOL are not
810 fully explained by improvements in the severity of depressive symptom suggesting that
811 interventions should go beyond the mere reduction of symptom severity and consider other factors
812 that contribute to QoL as targets for intervention. Maternal-specific measures of QOL could be

integrated into postpartum depression screening programs or routine postnatal care^{235, 236}. Indeed, QoL measures that allow a women to identify which areas of her life are most important to her, could be used to allow women to indicate where she would like to see improvements.²²⁹ Emerging studies have highlighted the beneficial effect of social support on QOL²³⁷, in addition to risk factors for reduced QOL such as younger age and lower socio-economic status in women with postpartum depression ²³⁸.

PPDs have economic considerations and can affect quality-adjusted life years (QALY)¹⁴². QALY takes into account how treatment affects quality and quantity of life, and accordingly, QoL measurement is necessary for studies of cost-effectiveness of treatments. Compelling data from the London School of Economics²³⁹ demonstrated the high economic costs of PPDs and the need to address the loss of QALYs of women and their children, by treatment and prevention of these disorders. This finding is particularly pertinent given the short and long-term effects of postpartum depression. Indeed, as most women recover from postpartum mood disorders, these disorders can become chronic in a subgroup of women²⁴⁰. One study demonstrated that, for each one-year cohort of births, perinatal depression, anxiety and psychosis cost the UK around £8.1 billion in the long-term.²³⁹

[H1] Outlook

The postpartum period is a vulnerable time for onset of psychiatric illness. Indeed, postpartum mood and anxiety are heterogeneous and might be triggered by biopsychosocial factors including a vulnerability to the robust endocrine and immune-related changes that occur at childbirth. The heterogeneity of these disorders requires a thoughtful approach to assessment and treatment planning that includes the clinical presentation, family and personal psychiatric history, other psychosocial risk factors (including history of trauma), and awareness of potential biological or genetic contributions that might influence risk and vulnerability.

838 The precise vulnerability that leads to some women developing PPDs is currently unknown and
839 novel research approaches are needed to identify the underlying pathophysiology of both
840 prepartum and postpartum anxiety, depression and psychosis. This will require a multi-faceted
841 approach in preclinical, clinical and translational research, to determine the mechanisms behind
842 the neurobiology and physiological correlates of PPDs, and the observed peripartum mood and
843 mothering behaviors. Additionally, these strategies must address the differences in the timing of
844 symptom onset and the diverse types of symptoms.

845 Given the morbidity and mortality of postpartum psychosis, episodes of psychosis might be best
846 considered to represent women with a bipolar disorder diathesis with a puerperal trigger.

847 Understanding this trigger will be beneficial and should allow the development of new treatments
848 and, ultimately, enable the prevention of psychosis or prevent unfavourable outcomes in women at
849 high risk. Effective evidence based treatment approaches are available for psychosis and
850 depression, including psychopharmacology, psychotherapy and ECT and circadian manipulation.

851 However, postpartum depression and postpartum psychosis require different and targeted
852 treatment approaches and therefore, bipolarity must be considered in the evaluation and
853 management of all women with postpartum mood and anxiety disorders. In addition, primary
854 treatment goals should include the limitation of the current episode and the prevention of future
855 episodes (including unipolar or bipolar disease with multiple episodes, and chronic anxiety).

856 Whether there a continuum of severity between postpartum depression and postpartum psychosis,
857 or whether these disorders represent different conditions with different aetiological factors requires
858 further study.

859 A potential barrier to the engagement and retention of women in the treatment of postpartum mood
860 disorders is stigma. Understand this stigma and the fear that women have regarding postpartum
861 mood disorders is essential. The voices of women with postpartum mood disorders must be
862 incorporated into the development of services to ensure the needs of women, their infants and
863 families are met^{241, 242}.

To date, the amount of research provides an important road map for PPDs in general, and guidelines for screening or identification and treatment for perinatal depression in many countries gives a strong mandate to improve mental health care for all women in the perinatal period. Thus, developing effective strategies in low, middle and high income countries that allow the delivery of targeted therapies to women with different clinical phenotypes and severity of PPDs is imperative. In addition, whether the current ICD-10 and DSM-5 classification systems are adequate for detecting specific phenotypes or diagnostic groups of patients should be evaluated. We should also consider that PPDs might be phenotypically different than psychiatric disorders that begin during pregnancy. Indeed, disorders that occur postpartum might have unique characteristics in epidemiology, pathophysiology, psychosocial contributions, prevention and management than disorders that occur during pregnancy.

In summary, PPDs are morbid and costly disorders. Advocating for early identification and screening that begins in pregnancy to identify women at risk, in addition to timely and effective treatments of PPDs is essential. Given the recent advances in knowledge, this an incredibly exciting time for research in perinatal mood disorders. New approaches might allow the identification of the underlying causes of postpartum mood disorders, which could lead efforts to identify women at risk and personalize treatment. Although genetic, biological and hormonal signals likely have an important role in risk of these disorders, psychosocial contributions including the current impact of lifetime stressors must be part of comprehensive work-up and treatment plan. The social determinants of postpartum mood disorders, such as poverty, domestic violence, poor housing, and insecure migrant status, should also be assessed as part of routine practice of maternal health care for all women. Finally, we must recognize that maternal mental health is necessary for the physical and mental health of mothers, infants and families¹⁷ and advocating and protecting this population is our obligation.

References

1. Munk-Olsen, T., Laursen, T.M., Pedersen, C.B., Mors, O. & Mortensen, P.B. New parents and mental disorders: a population-based register study. *The journal of the American Medical Association* **296**, 2582-2589 (2006).
- This paper was the first to use a population based register cohort to demonstrate the first month postpartum is the highest risk time for onset of postpartum psychiatric illness.***
2. Howard L.M., et al. The accuracy of the Whooley questions and the Edinburgh Postnatal Depression Scale in identifying mental disorders in early pregnancy. *B. J. Psych* **212**, 50-56 (2018)
3. Heron, J., O'Connor, T.G., Evans, J., Golding, J. & Glover, V. The course of anxiety and depression through pregnancy and the postpartum in a community sample. *Journal of affective disorders* **80**, 65-73 (2004).
4. Guintivano, J. et al. Adverse life events, psychiatric history, and biological predictors of postpartum depression in an ethnically diverse sample of postpartum women. *Psychol Med*, 1-14 (2017).
5. Perry, A. et al. Adverse childhood life events and postpartum psychosis in bipolar disorder. *J Affect Disord* **205**, 69-72 (2016).
6. Sawyer, A., Ayers, S. & Smith, H. Pre- and postnatal psychological wellbeing in Africa: a systematic review. *J Affect Disord* **123**, 17-29 (2010).
7. Johannsen, B.M. et al. All-Cause Mortality in Women With Severe Postpartum Psychiatric Disorders. *Am J Psychiatry* **173**, 635-42 (2016).
8. Gaynes, B.N. et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. *Evid Rep Technol Assess (Summ)*, 1-8 (2005).
9. Chesney, E., Goodwin, G.M. & Fazel, S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. *World Psychiatry* **13**, 153-60 (2014).
10. Parsons, C.E., Young, K.S., Rochat, T.J., Kringelbach, M.L. & Stein, A. Postnatal depression and its effects on child development: a review of evidence from low- and middle-income countries. *Br Med Bull* **101**, 57-79 (2012).
11. Gavin, N.I. et al. Perinatal depression: a systematic review of prevalence and incidence. *Obstet Gynecol* **106**, 1071-83 (2005).
12. Meltzer-Brody, S. New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. *Dialogues Clin Neurosci* **13**, 89-100 (2011).
13. Meltzer-Brody, S. & Stringer, E.M. Global maternal, newborn, and child health. *N Engl J Med* **370**, 1072 (2014).
14. Norhayati, M.N., Hazlina, N.H., Asrenee, A.R. & Emilin, W.M. Magnitude and risk factors for postpartum symptoms: a literature review. *J Affect Disord* **175**, 34-52 (2015).
15. Bergink, V., Rasgon, N. & Wisner, K.L. Postpartum Psychosis: Madness, Mania, and Melancholia in Motherhood. *Am J Psychiatry* **173**, 1179-1188 (2016).
16. Jones, I., Chandra, P.S., Dazzan, P. & Howard, L.M. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. *Lancet* **384**, 1789-99 (2014).
- This paper provides an outstanding comprehensive review of the literature in bipolar disorder and other psychotic disorders in the perinatal period.***
17. Howard, L.M. et al. Non-psychotic mental disorders in the perinatal period. *Lancet* **384**, 1775-88 (2014).
- An excellent summary of non-psychotic mental disorders in the perinatal period.***
18. Wesseloo, R. et al. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis. *Am J Psychiatry* **173**, 117-27 (2016).
19. Stewart, D.E. & Vigod, S. Postpartum Depression. *N Engl J Med* **375**, 2177-2186 (2016).
20. Munk-Olsen, T. et al. Perinatal psychiatric episodes: a population-based study on treatment incidence and prevalence. *Transl Psychiatry* **6**, e919 (2016).

21. Fisher, J. et al. Prevalence and determinants of common perinatal mental disorders in women in low- and lower-middle-income countries: a systematic review. *Bull World Health Organ* **90**, 139G-149G (2012).
22. Franko, D.L. et al. Pregnancy complications and neonatal outcomes in women with eating disorders. *Am J Psychiatry* **158**, 1461-6 (2001).
23. Cox, J.L., Holden, J.M. & Sagovsky, R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. *Br.J.Psychiatry* **150**, 782-786 (1987).
24. Excellence, N.N.I.f.H.a.C. in The British Psychological Society and the Royal College of Psychiatrists (London, United Kingdom, 2014).
25. O'Connor, E., Rossom, R.C., Henninger, M., Groom, H.C. & Burda, B.U. Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* **315**, 388-406 (2016).
26. Liu, X. et al. Depression and Anxiety in the Postpartum Period and Risk of Bipolar Disorder: A Danish Nationwide Register-Based Cohort Study. *J Clin Psychiatry* **78**, e469-e476 (2017).
27. Sharma, V., Doobay, M. & Baczynski, C. Bipolar postpartum depression: An update and recommendations. *J Affect Disord* **219**, 105-111 (2017).
28. Dennis, C.L., Falah-Hassani, K. & Shiri, R. Prevalence of antenatal and postnatal anxiety: systematic review and meta-analysis. *Br J Psychiatry* **210**, 315-323 (2017).
29. Munk-Olsen, T., Laursen, T.M., Pedersen, C.B., Mors, O. & Mortensen, P.B. New Parents and Mental Disorders. A Population-Based Register Study. *JAMA* **296**, 2582-2589 (2006).
30. Harlow, B.L. et al. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior prepregnancy or prenatal psychiatric hospitalizations. *Arch.Gen.Psychiatry* **64**, 42-48 (2007).
31. Kendell, R.E., Chalmers, J.C. & Platz, C. Epidemiology of puerperal psychoses. *Br.J.Psychiatry* **150**, 662-673 (1987).
32. Valdimarsdottir, U., Hultman, C.M., Harlow, B., Cnattingius, S. & Sparen, P. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: a population-based study. *PLoS.Med.* **6**, e13 (2009).
33. Bergink, V., Boyce, P. & Munk-Olsen, T. Postpartum psychosis: a valuable misnomer. *Aust N Z J Psychiatry* **49**, 102-3 (2015).
34. Di Florio, A. et al. Perinatal episodes across the mood disorder spectrum. *Journal of the American Medical Association: Psychiatry* **70**, 168-75 (2013).
35. Munk-Olsen, T. et al. Risks and predictors of readmission for a mental disorder during the postpartum period. *Archives of general psychiatry* **66**, 189-95 (2009).
36. Florio, A.D., Munk-Olsen, T. & Bergink, V. The birth of a psychiatric orphan disorder: postpartum psychosis. *Lancet Psychiatry* **3**, 502 (2016).
37. Lysell, H. et al. Maternal suicide - Register based study of all suicides occurring after delivery in Sweden 1974-2009. *PLoS One* **13**, e0190133 (2018).
38. Grigoriadis, S. et al. Perinatal suicide in Ontario, Canada: a 15-year population-based study. *CMAJ* **189**, E1085-E1092 (2017).
39. Kimmel, M. et al. Family history, not lack of medication use, is associated with the development of postpartum depression in a high-risk sample. *Arch Womens Ment Health* (2014).
40. Viguera, A.C. et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. *Am J Psychiatry* **164**, 1817-24; quiz 1923 (2007).
41. Fonagy, P., Sled, M. & Baradon, T. Randomized Controlled Trial of Parent-Infant Psychotherapy for Parents with Mental Health Problems and Young Infants. *Infant Ment Health J* **37**, 97-114 (2016).
42. Stein, A. et al. Effects of perinatal mental disorders on the fetus and child. *Lancet* **384**, 1800-19 (2014).

An outstanding review of the adverse impact on fetus and child due to perinatal mental illness.

- 991 43. Faisal-Cury, A., Menezes, P.R., d'Oliveira, A.F., Schraiber, L.B. & Lopes, C.S. Temporal
992 relationship between intimate partner violence and postpartum depression in a sample of low
993 income women. *Matern Child Health J* **17**, 1297-303 (2013).
- 994 44. Onoye, J.M., Goebert, D., Morland, L., Matsu, C. & Wright, T. PTSD and postpartum mental health
995 in a sample of Caucasian, Asian, and Pacific Islander women. *Arch Womens Ment Health* **12**,
996 393-400 (2009).
- 997 45. Gonzalez, A., Jenkins, J.M., Steiner, M. & Fleming, A.S. Maternal early life experiences and
998 parenting: the mediating role of cortisol and executive function. *J Am Acad Child Adolesc*
999 *Psychiatry* **51**, 673-82 (2012).
- 1000 46. Hipwell, A.E., Goossens, F.A., Melhuish, E.C. & Kumar, R. Severe maternal psychopathology and
1001 infant-mother attachment. *Development and psychopathology* **12**, 157-75 (2000).
- 1002 47. Goodman, S.H. et al. Maternal depression and child psychopathology: a meta-analytic review.
1003 *Clin Child Fam Psychol Rev* **14**, 1-27 (2011).
- 1004 48. Muzik, M. et al. Psychopathology and parenting: An examination of perceived and observed
1005 parenting in mothers with depression and PTSD. *J Affect Disord* **207**, 242-250 (2017).
- 1006 49. Yim, I.S., Tanner Stapleton, L.R., Guardino, C.M., Hahn-Holbrook, J. & Dunkel Schetter, C.
1007 Biological and psychosocial predictors of postpartum depression: systematic review and call
1008 for integration. *Annu Rev Clin Psychol* **11**, 99-137 (2015).
- 1009 50. Xie, R.H. et al. Prenatal family support, postnatal family support and postpartum depression.
1010 *Aust N Z J Obstet Gynaecol* **50**, 340-5 (2010).
- 1011 51. Rogathi, J.J. et al. Postpartum depression among women who have experienced intimate
1012 partner violence: A prospective cohort study at Moshi, Tanzania. *J Affect Disord* **218**, 238-245
1013 (2017).
- 1014 52. Fiala, A., Svancara, J., Klanova, J. & Kasparek, T. Sociodemographic and delivery risk factors for
1015 developing postpartum depression in a sample of 3233 mothers from the Czech ELSPAC study.
1016 *BMC Psychiatry* **17**, 104 (2017).
- 1017 53. Craddock, N. & Forty, L. Genetics of affective (mood) disorders. *Eur J Hum Genet* **14**, 660-8
1018 (2006).
- 1019 54. Lichtenstein, P. et al. Common genetic determinants of schizophrenia and bipolar disorder in
1020 Swedish families: a population-based study. *Lancet* **373**, 234-9 (2009).
- 1021 55. Byrne, E.M. et al. Applying polygenic risk scores to postpartum depression. *Arch Womens Ment*
1022 *Health* (2014).
- 1023 56. Forty, L. et al. Familiality of postpartum depression in unipolar disorder: results of a family
1024 study. *The American Journal of Psychiatry* **163**, 1549-1553 (2006).
- 1025 57. Mahon, P.B. et al. Genome-wide linkage and follow-up association study of postpartum mood
1026 symptoms. *The American journal of psychiatry* **166**, 1229-37 (2009).
- 1027 58. Treloar, S.A., Martin, N.G., Bucholz, K.K., Madden, P.A. & Heath, A.C. Genetic influences on post-
1028 natal depressive symptoms: findings from an Australian twin sample. *Psychol Med* **29**, 645-54
1029 (1999).
- 1030 59. Viktorin, A. et al. Heritability of Perinatal Depression and Genetic Overlap With Nonperinatal
1031 Depression. *Am J Psychiatry*, appiajp201515010085 (2015).
- 1032 ***This paper showed the increased heritability of perinatal depression compared to depression***
1033 ***outside of the perinatal period.***
- 1034 60. Jones, I. et al. Bipolar affective puerperal psychosis: genome-wide significant evidence for
1035 linkage to chromosome 16. *The American Journal of Psychiatry* **164**, 1099-1104 (2007).
- 1036 61. Jones, I., Craddock, N., Jones, I. & Craddock, N. Searching for the puerperal trigger: molecular
1037 genetic studies of bipolar affective puerperal psychosis. *Psychopharmacology Bulletin* **40**, 115-
1038 28 (2007).
- 1039 62. Consortium, P.D.A.T.C.a.T.P. Heterogeneity of postpartum depression: a latent class analysis.
1040 *Lancet Psychiatry* **2**, 59-67 (2015).

- 1041 **One of the first papers to examine the heterogeneity of postpartum depression using an**
1042 **international consortium of 19 international sites. Was featured in New York Times.**
- 1043 63. Putnam, K.T. et al. Clinical phenotypes of perinatal depression and time of symptom onset:
1044 analysis of data from an international consortium. *Lancet Psychiatry* **4**, 477-485 (2017).
- 1045 64. Geronimus, A.T., Hicken, M., Keene, D. & Bound, J. "Weathering" and age patterns of allostatic
1046 load scores among blacks and whites in the United States. *Am J Public Health* **96**, 826-33
1047 (2006).
- 1048 65. Perroud, N. et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with
1049 a history of childhood maltreatment: a link with the severity and type of trauma. *Transl*
1050 *Psychiatry* **1**, e59 (2011).
- 1051 66. Schwaiger, M. et al. Altered Stress-Induced Regulation of Genes in Monocytes in Adults with a
1052 History of Childhood Adversity. *Neuropsychopharmacology* **41**, 2530-40 (2016).
- 1053 67. Vincent, J. et al. Assessing the contributions of childhood maltreatment subtypes and
1054 depression case-control status on telomere length reveals a specific role of physical neglect. *J*
1055 *Affect Disord* **213**, 16-22 (2017).
- 1056 68. Mitchell, A.M., Kowalsky, J.M., Epel, E.S., Lin, J. & Christian, L.M. Childhood adversity, social
1057 support, and telomere length among perinatal women. *Psychoneuroendocrinology* **87**, 43-52
1058 (2017).
- 1059 69. Osborne, L. et al. Replication of Epigenetic Postpartum Depression Biomarkers and Variation
1060 with Hormone Levels. *Neuropsychopharmacology* **41**, 1648-58 (2016).
- 1061 70. Guintivano, J., Arad, M., Gould, T.D., Payne, J.L. & Kaminsky, Z.A. Antenatal prediction of
1062 postpartum depression with blood DNA methylation biomarkers. *Mol Psychiatry* **19**, 560-7
1063 (2014).
- 1064 71. Murray, G. & Harvey, A. Circadian rhythms and sleep in bipolar disorder. *Bipolar Disord* **12**,
1065 459-72 (2010).
- 1066 72. Lewis, K.J., Foster, R.G. & Jones, I.R. Is sleep disruption a trigger for postpartum psychosis? *Br J*
1067 *Psychiatry* **208**, 409-11 (2016).
- 1068 73. Marques, M. et al. Is insomnia in late pregnancy a risk factor for postpartum
1069 depression/depressive symptomatology? *Psychiatry Res* **186**, 272-80 (2011).
- 1070 74. Parry, B.L. et al. Plasma melatonin circadian rhythm disturbances during pregnancy and
1071 postpartum in depressed women and women with personal or family histories of depression.
1072 *Am J Psychiatry* **165**, 1551-8 (2008).
- 1073 75. Thomas, K.A. & Burr, R.L. Melatonin level and pattern in postpartum versus nonpregnant
1074 nulliparous women. *J Obstet Gynecol Neonatal Nurs* **35**, 608-15 (2006).
- 1075 76. Sharkey, K.M., Pearlstein, T.B. & Carskadon, M.A. Circadian phase shifts and mood across the
1076 perinatal period in women with a history of major depressive disorder: A preliminary
1077 communication. *Journal of Affective Disorders* **150**, 1103-1108 (2013).
- 1078 77. Bloch, M. et al. Effects of gonadal steroids in women with a history of postpartum depression.
1079 *The American Journal of Psychiatry* **157**, 924-30 (2000).
- 1080 **The first paper to demonstrate differential sensitivity to fluctuations in gonadal hormones in**
1081 **vulnerable women using hormonal manipulation.**
- 1082 78. Sohrabji, F., Miranda, R.C. & Toran-Allerand, C.D. Estrogen differentially regulates estrogen and
1083 nerve growth factor receptor mRNAs in adult sensory neurons. *J Neurosci* **14**, 459-71 (1994).
- 1084 79. Shimizu, E. et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in
1085 depressed patients with or without antidepressants. *Biol Psychiatry* **54**, 70-5 (2003).
- 1086 80. Finocchi, C. & Ferrari, M. Female reproductive steroids and neuronal excitability. *Neurol Sci* **32**
1087 **Suppl 1**, S31-5 (2011).
- 1088 81. Pluchino, N. et al. Steroid hormones and BDNF. *Neuroscience* **239**, 271-9 (2013).
- 1089 82. Epperson, C.N. et al. Preliminary evidence of reduced occipital GABA concentrations in
1090 puerperal women: a 1H-MRS study. *Psychopharmacology (Berl)* **186**, 425-33 (2006).

- 1091 83. Schiller, C.E., Meltzer-Brody, S. & Rubinow, D.R. The role of reproductive hormones in
1092 postpartum depression. *CNS Spectr* **20**, 48-59 (2015).
- 1093 84. Paul, S.M. & Purdy, R.H. Neuroactive steroids. *FASEB J* **6**, 2311-22 (1992).
- 1094 85. Majewska, M.D., Harrison, N.L., Schwartz, R.D., Barker, J.L. & Paul, S.M. Steroid hormone
1095 metabolites are barbiturate-like modulators of the GABA receptor. *Science* **232**, 1004-7 (1986).
- 1096 86. Deligiannidis, K.M. et al. Peripartum neuroactive steroid and gamma-aminobutyric acid profiles
1097 in women at-risk for postpartum depression. *Psychoneuroendocrinology* **70**, 98-107 (2016).
- 1098 87. Luisi, S. et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at
1099 delivery, and in hypertensive patients. *J Clin Endocrinol Metab* **85**, 2429-33 (2000).
- 1100 88. Nappi, R.E. et al. Serum allopregnanolone in women with postpartum "blues". *Obstet Gynecol*
1101 **97**, 77-80 (2001).
- 1102 89. Maguire, J., Mody, I., Maguire, J. & Mody, I. GABA(A)R plasticity during pregnancy: relevance to
1103 postpartum depression. *Neuron* **59**, 207-13 (2008).
- 1104 90. Paoletti, A.M. et al. Observational study on the stability of the psychological status during
1105 normal pregnancy and increased blood levels of neuroactive steroids with GABA-A receptor
1106 agonist activity. *Psychoneuroendocrinology* **31**, 485-92 (2006).
- 1107 91. Kanes, S.J. et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe
1108 postpartum depression. *Hum Psychopharmacol* **32** (2017).
- 1109 92. Kanes, S. et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised
1110 controlled trial. *Lancet* **390**, 480-489 (2017).
- 1111 93. Algoe, S.B. & Way, B.M. Evidence for a role of the oxytocin system, indexed by genetic variation
1112 in CD38, in the social bonding effects of expressed gratitude. *Soc Cogn Affect Neurosci* **9**, 1855-
1113 61 (2014).
- 1114 94. Cox, E.Q. et al. Oxytocin and HPA stress axis reactivity in postpartum women.
1115 *Psychoneuroendocrinology* **55**, 164-72 (2015).
- 1116 95. Zelkowitz, P. et al. Psychosocial stress moderates the relationships between oxytocin, perinatal
1117 depression, and maternal behavior. *Horm Behav* **66**, 351-60 (2014).
- 1118 96. Wei, S.M. et al. Brain-derived neurotrophic factor Val66Met genotype and ovarian steroids
1119 interactively modulate working memory-related hippocampal function in women: a
1120 multimodal neuroimaging study. *Mol Psychiatry* (2017).
- 1121 97. Sacher, J. et al. Relationship of monoamine oxidase-A distribution volume to postpartum
1122 depression and postpartum crying. *Neuropsychopharmacology* **40**, 429-35 (2015).
- 1123 98. Wonch, K.E. et al. Postpartum depression and brain response to infants: Differential amygdala
1124 response and connectivity. *Soc Neurosci* **11**, 600-17 (2016).
- 1125 99. Musser, E.D., Kaiser-Laurent, H. & Ablow, J.C. The neural correlates of maternal sensitivity: an
1126 fMRI study. *Dev Cogn Neurosci* **2**, 428-36 (2012).
- 1127 100. Pawluski, J.L., Lonstein, J.S. & Fleming, A.S. The Neurobiology of Postpartum Anxiety and
1128 Depression. *Trends Neurosci* **40**, 106-120 (2017).
- 1129 101. Roomruangwong, C. et al. A neuro-immune, neuro-oxidative and neuro-nitrosative model of
1130 prenatal and postpartum depression. *Prog Neuropsychopharmacol Biol Psychiatry* (2017).
- 1131 102. Glynn, L.M., Davis, E.P. & Sandman, C.A. New insights into the role of perinatal HPA-axis
1132 dysregulation in postpartum depression. *Neuropeptides* **47**, 363-70 (2013).
- 1133 103. Ferguson, E.H. et al. HPA axis reactivity to pharmacologic and psychological stressors in
1134 euthymic women with histories of postpartum versus major depression. *Arch Womens Ment*
1135 *Health* **20**, 411-420 (2017).
- 1136 104. Iliadis, S.I. et al. Associations between a polymorphism in the hydroxysteroid (11-beta)
1137 dehydrogenase 1 gene, neuroticism and postpartum depression. *Journal of Affective Disorders*
1138 **207**, 141-147 (2017).
- 1139 105. Zaconeta, A.M. et al. Cerebrospinal Fluid CRH Levels in Late Pregnancy Are Not Associated With
1140 New-Onset Postpartum Depressive Symptoms. *J Clin Endocrinol Metab* **100**, 3159-64 (2015).

- 1141 106. Hahn-Holbrook, J., Fox, M. & Glynn, L.M. Letter to the Editor: Demonstration of Elevated
1142 Cerebrospinal Fluid CRH Levels During Pregnancy Provides Support for (Not Against) the Link
1143 Between CRH and Postpartum Depression. *J Clin Endocrinol Metab* **101**, L5-6 (2016).
- 1144 107. Pedersen, C. et al. Late pregnancy thyroid-binding globulin predicts perinatal depression.
1145 *Psychoneuroendocrinology* **65**, 84-93 (2016).
- 1146 108. Bergink, V. et al. Comorbidity of autoimmune thyroid disorders and psychiatric disorders
1147 during the postpartum period: a Danish nationwide register-based cohort study. *Psychol Med*,
1148 1-9 (2017).
- 1149 109. Wesseloo, R., Kamperman, A.M., Bergink, V. & Pop, V.J.M. Thyroid peroxidase antibodies during
1150 early gestation and the subsequent risk of first-onset postpartum depression: A prospective
1151 cohort study. *J Affect Disord* **225**, 399-403 (2018).
- 1152 110. Groer, M.W. & Vaughan, J.H. Positive thyroid peroxidase antibody titer is associated with
1153 dysphoric moods during pregnancy and postpartum. *J Obstet Gynecol Neonatal Nurs* **42**, E26-32
1154 (2013).
- 1155 111. Anderson, G. & Maes, M. Postpartum depression: Psychoneuroimmunological underpinnings
1156 and treatment. *Neuropsychiatric Disease and Treatment* **9**, 277-287 (2013).
- 1157 112. Osborne, L.M. & Monk, C. Perinatal depression--the fourth inflammatory morbidity of
1158 pregnancy?: Theory and literature review. *Psychoneuroendocrinology* **38**, 1929-52 (2013).
- 1159 113. Haim, A. et al. A survey of neuroimmune changes in pregnant and postpartum female rats.
1160 *Brain Behav Immun* **59**, 67-78 (2017).
- 1161 114. Nilsen-Hamilton, M. et al. Tissue involution and the acute phase response. *Ann N Y Acad Sci*
1162 **995**, 94-108 (2003).
- 1163 115. Skalkidou, A. et al. Risk of postpartum depression in association with serum leptin and
1164 interleukin-6 levels at delivery: a nested case-control study within the UPPSAT cohort.
1165 *Psychoneuroendocrinology* **34**, 1329-37 (2009).
- 1166 116. Maes, M. et al. Immune activation in the early puerperium is related to postpartum anxiety and
1167 depressive symptoms. *Psychoneuroendocrinology* **25**, 121-37 (2000).
- 1168 117. Maes, M. et al. Effects of pregnancy and delivery on serum concentrations of Clara Cell Protein
1169 (CC16), an endogenous anticytokine: lower serum CC16 is related to postpartum depression.
1170 *Psychiatry Res* **87**, 117-27 (1999).
- 1171 118. De Vriese, S.R., Christophe, A.B. & Maes, M. Lowered serum n-3 polyunsaturated fatty acid
1172 (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered
1173 n-PUFAs are related to major depression. *Life Sci* **73**, 3181-7 (2003).
- 1174 119. Corwin, E.J. et al. Bidirectional psychoneuroimmune interactions in the early postpartum
1175 period influence risk of postpartum depression. *Brain Behav Immun* **49**, 86-93 (2015).
- 1176 120. Bergink, V. et al. Pre-eclampsia and first-onset postpartum psychiatric episodes: a Danish
1177 population-based cohort study. *Psychol Med* **45**, 3481-9 (2015).
- 1178 121. Bergink, V. et al. Autoimmune Encephalitis in Postpartum Psychosis. *Am J Psychiatry* **172**, 901-
1179 8 (2015).
- 1180 122. Bergink, V. et al. Immune system dysregulation in first-onset postpartum psychosis. *Biol*
1181 *Psychiatry* **73**, 1000-7 (2013).
- 1182 123. Uchino, B.N., Cacioppo, J.T. & Kiecolt-Glaser, J.K. The relationship between social support and
1183 physiological processes: a review with emphasis on underlying mechanisms and implications
1184 for health. *Psychol Bull* **119**, 488-531 (1996).
- 1185 124. Dickerson, S.S., Zoccola, P.M. & Hooker, E. in *The Oxford handbook of positive psychology*
1186 (2009).
- 1187 125. Association, A.P. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)* (American
1188 Psychiatric Publishing, Arlington, VA, 2013).
- 1189 126. WHO, W.H.O. (World Health Organization, Geneva, 1992) .
- 1190 127. Falah-Hassani, K., Shiri, R. & Dennis, C.L. The prevalence of antenatal and postnatal co-morbid
1191 anxiety and depression: a meta-analysis. *Psychological Medicine* **47**, 2041-2053 (2017).

- 1192 128. Howard, L.M., Megnin-Viggars, O., Symington, I., Pilling, S. & Guideline Development, G.
1193 Antenatal and postnatal mental health: summary of updated NICE guidance. *BMJ* **349**, g7394
1194 (2014).
- 1195 129. Di Florio, A. et al. The impact of education, country, race and ethnicity on the self-report of
1196 postpartum depression using the Edinburgh Postnatal Depression Scale. *Psychol Med*, 1-13
1197 (2016).
- 1198 130. Heron, J., McGuinness, M., Blackmore, E.R., Craddock, N. & Jones, I. Early postpartum symptoms
1199 in puerperal psychosis. *BJOG* **115**, 348-53 (2008).
- 1200 131. Bergink, V., Lambregtse-van den Berg, M.P., Koorengevel, K.M., Kupka, R. & Kushner, S.A. First-
1201 onset psychosis occurring in the postpartum period: a prospective cohort study. *J Clin*
1202 *Psychiatry* **72**, 1531-7 (2011).
- 1203 132. Kamperman, A.M., Veldman-Hoek, M.J., Wesseloo, R., Robertson Blackmore, E. & Bergink, V.
1204 Phenotypical characteristics of postpartum psychosis: A clinical cohort study. *Bipolar Disord*
1205 (2017).
- 1206 133. Feeney, E.J., Groman, S.M., Taylor, J.R. & Corlett, P.R. Explaining Delusions: Reducing
1207 Uncertainty Through Basic and Computational Neuroscience. *Schizophr Bull* **43**, 263-272
1208 (2017).
- 1209 134. Muzik, M. et al. Ptsd Symptoms across Pregnancy and Early Postpartum among Women with
1210 Lifetime Ptsd Diagnosis. *Depress Anxiety* **33**, 584-91 (2016).
- 1211 135. Kendall-Tackett, K.A. Violence against women and the perinatal period: the impact of lifetime
1212 violence and abuse on pregnancy, postpartum, and breastfeeding. *Trauma Violence Abuse* **8**,
1213 344-53 (2007).
- 1214 136. Schofield, C.A., Battle, C.L., Howard, M. & Ortiz-Hernandez, S. Symptoms of the anxiety
1215 disorders in a perinatal psychiatric sample: a chart review. *J Nerv Ment Dis* **202**, 154-60 (2014).
- 1216 137. McGarry, J., Kim, H., Sheng, X., Egger, M. & Baksh, L. Postpartum depression and help-seeking
1217 behaviour. *Journal of Midwifery and Women's Health* **54**, 50-56 (2009).
- 1218 138. Dennis, C.L. & Hodnett, E. Psychosocial and psychological interventions for treating postpartum
1219 depression. *Cochrane Database of Systematic Reviews* **Issue 4** (2007).
- 1220 139. Guidelines, B.B.C.P. (ed. Blue, B.) (2011).
- 1221 140. Siu, A.L. et al. Screening for Depression in Adults: US Preventive Services Task Force
1222 Recommendation Statement. *JAMA* **315**, 380-7 (2016).
- 1223 141. NICE. Antenatal and postnatal mental health: Clinical management and service guidance. The
1224 British Psychological Society & The Royal College of Psychiatrists. (National Institute for Health
1225 and Care Excellence (NICE). <http://guidance.nice.org.uk/cg192.www.nice.org.uk/CG45>, 2014).
- 1226 142. Milgrom, J. & Gemmill, A.W. (eds.) Identifying Perinatal Depression and Anxiety: Evidence-
1227 based Practice in Screening, Psychosocial Assessment and Management (Wiley-Blackwell,
1228 Chichester, 2015).
- 1229 ***An outstanding textbook on perinatal mental health that summarizes the literature on sceening,***
1230 ***psychosocial assessment and management.***
- 1231 143. Alliance, M.M.H.
- 1232 144. Screening for perinatal depression: a missed opportunity (Lancet. 2016 Feb 6;387(10018):505.
1233 doi: 10.1016/S0140-6736(16)00265-8).
- 1234 145. Cox, J. & Holden, J. Perinatal Mental Health. A Guide to the Edinburgh Postnatal Depression
1235 Scale (EPDS) (Gaskell, London, 2003).
- 1236 146. Myers, E. et al. (Agency for Healthcare Research and Quality, Rockville, MD, 2013).
- 1237 147. Hewitt, C. et al. Methods to identify postnatal depression in primary care: an integrated
1238 evidence synthesis and value of information analysis. *Health Technology Assessment* **13**, 1-145,
1239 147-230 (2009).
- 1240 148. Howard, L.M., Flach, C., Mehay, A., Sharp, D. & Tylee, A. The prevalence of suicidal ideation
1241 identified by the Edinburgh Postnatal Depression Scale in postpartum women in primary care:
1242 findings from the RESPOND trial. *BMC pregnancy and childbirth* **11**, 57 (2011).

- 1243 149. Brealey, S.D., Hewitt, C., Green, J.M., Morrell, J. & Gilbody, S. Screening for postnatal
1244 depression—Is it acceptable to women and healthcare professionals? A systematic review and
1245 meta-synthesis. *Journal of Reproductive and Infant Psychology* **28**, 328-344 (2010).
- 1246 150. Gemmill, A.W., Leigh, B., Ericksen, J. & Milgrom, J. A survey of the clinical acceptability of
1247 screening for postnatal depression in depressed and non-depressed women. *BMC Public Health*
1248 **6**, 211 (2006).
- 1249 151. Wisner, K. et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with
1250 screen-positive depression findings. *JAMA Psychiatry* **70**, 490-498 (2013).
- 1251 152. Beck, C.T. & Gable, R.K. Postpartum Depression Screening Scale: development and
1252 psychometric testing. *Nursing research* **49**, 272-82 (2000).
- 1253 153. Beck, A.T., Steer, R.A. & Brown, G.K. Manual for the BDI-II (The Psychological Corporation, San
1254 Antonio, TX, 1996).
- 1255 154. Kroenke, K., Spitzer, R.L. & Williams, J.B. The PHQ-9: validity of a brief depression severity
1256 measure. *Journal of General Internal Medicine* **16**, 606-13 (2001).
- 1257 155. Yawn, B.P. et al. TRIPPD: A practice-based network effectiveness study of postpartum
1258 depression screening and management. *The Annals of Family Medicine* **10**, 320-329 (2012).
- 1259 156. Whooley, M., Avins, A. & Miranda, J. Case-finding instruments for depression: two questions are
1260 as good as many. *J Gen Intern Med* **12**, 439-445 (1997).
- 1261 157. Arroll, B., Smith, F.G., Kerse, N., Fishman, T. & Gunn, J. Effect of the addition of a “help” question
1262 to two screening questions on specificity for diagnosis of depression in general practice:
1263 diagnostic validity study. *BMJ* **331**, 884 (2005).
- 1264 158. Falah-Hassani, K., Shiri, R. & Dennis, C.L. The prevalence of antenatal and postnatal co-morbid
1265 anxiety and depression: a meta-analysis. *Psychol Med* **47**, 2041-2053 (2017).
- 1266 159. Milgrom, J. et al. Feasibility study and pilot randomised trial of an antenatal depression
1267 treatment with infant follow-up. *Archives of Women's Mental Health* **18**, 717-30 (2015).
- 1268 160. Matthey, S., Fisher, J. & Rowe, H. Using the Edinburgh postnatal depression scale to screen for
1269 anxiety disorders: Conceptual and methodological considerations. *Journal of Affective Disorders*
1270 **146**, 224-230 (2013).
- 1271 161. Somerville, S. et al. Detecting the severity of perinatal anxiety with the Perinatal Anxiety
1272 Screening Scale (PASS). *Journal of Affective Disorders* **186**, 18-25 (2015).
- 1273 162. Spitzer, R.L., Kroenke, K., Williams, J.B. & Lowe, B. A brief measure for assessing generalized
1274 anxiety disorder: the GAD-7. *Arch Intern Med* **166**, 1092-7 (2006).
- 1275 163. Lord, C., Rieder, A., Hall, G.B., Soares, C.N. & Steiner, M. Piloting the perinatal obsessive-
1276 compulsive scale (POCS): development and validation. *J Anxiety Disord* **25**, 1079-84 (2011).
- 1277 164. Meltzer-Brody, S., Churchill, E. & Davidson, J.R. Derivation of the SPAN, a brief diagnostic
1278 screening test for post-traumatic stress disorder. *Psychiatry Res* **88**, 63-70 (1999).
- 1279 165. Frey, B.N., Simpson, W., Wright, L. & Steiner, M. Sensitivity and specificity of the Mood Disorder
1280 Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum
1281 period. *Journal of Clinical Psychiatry* **73**, 1456-1461 (2012).
- 1282 166. Clark, C.T. et al. Does Screening with the MDQ and EPDS Improve Identification of Bipolar
1283 Disorder in an Obstetrical Sample? *Depression and Anxiety* **32**, 518-26 (2015).
- 1284 167. Chessick, C.A. & Dimidjian, S. Screening for bipolar disorder during pregnancy and the
1285 postpartum period. *Arch Women Ment Health* **13**, 233-248 (2010).
- 1286 168. Kelly, E. & Sharma, V. Diagnosis and treatment of postpartum bipolar depression. *Expert review*
1287 *of neurotherapeutics* **10**, 1045-1051 (2010).
- 1288 169. Stanton, K. & Watson, D. Explicating the structure and relations of the Mood Disorder
1289 Questionnaire: Implications for screening for bipolar and related disorders. *J Affect Disord* **220**,
1290 72-78 (2017).
- 1291 170. Yawn, B.P., LaRusso, E.M., Bertram, S.L. & Bobo, W.V. in Identifying Perinatal Depression and
1292 Anxiety 32-50 (John Wiley & Sons, Ltd, 2015).

- 1293 171. Milgrom, J. & Gemmill, A.W. in Applied Topics in Health Psychology (eds. Caltabiano, M. &
1294 Ricciardelli, L.) 212-227 (Wiley, Chichester, 2013).
- 1295 172. O'Connor, E., Rossom, R.C., Henninger, M., Groom, H.C. & Burda, B.U. Primary care screening for
1296 and treatment of depression in pregnant and postpartum women evidence report and
1297 systematic review for the US preventive services task force. *JAMA - Journal of the American*
1298 *Medical Association* **315**, 388-406 (2016).
- 1299 ***The paper that documented the overwhelming and sufficient evidence and need for routine***
1300 ***screening of all perinatal women.***
- 1301 173. Milgrom, J. et al. Internet Cognitive Behavioral Therapy for Women With Postnatal Depression:
1302 A Randomized Controlled Trial of MumMoodBooster. *J Med Internet Res* **18**, e54 (2016).
- 1303 174. Wilkinson, A., Anderson, S. & Wheeler, S.B. Screening for and Treating Postpartum Depression
1304 and Psychosis: A Cost-Effectiveness Analysis. *Maternal and Child Health Journal* **21**, 903-914
1305 (2017).
- 1306 175. Werner, E., Miller, M., Osborne, L.M., Kuzava, S. & Monk, C. Preventing postpartum depression:
1307 review and recommendations. *Archives of Women's Mental Health* **18**, 41-60 (2015).
- 1308 176. Dennis, C.L. & Dowswell, T. Psychosocial and psychological interventions for preventing
1309 postpartum depression. *Cochrane Database Syst Rev*, CD001134 (2013).
- 1310 177. Morrell, C.J. et al. A systematic review, evidence synthesis and meta-analysis of quantitative
1311 and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and
1312 acceptability of interventions to prevent postnatal depression. *Health Technology Assessment*
1313 **20**, 1-414 (2016).
- 1314 178. Payne, J.L. Recent Advances and Controversies in Peripartum Depression. *Curr Obstet Gynecol*
1315 *Rep* **5**, 250-256 (2016).
- 1316 179. Wisner, K.L. & Wheeler, S.B. Prevention of recurrent postpartum major depression. *Hosp*
1317 *Community Psychiatry* **45**, 1191-6 (1994).
- 1318 180. Dennis, C.L. & Dowswell, T. Interventions (other than pharmacological, psychosocial or
1319 psychological) for treating antenatal depression. *Cochrane Database Syst Rev*, CD006795
1320 (2013).
- 1321 181. Kwan, B.M., Dimidjian, S. & Rizvi, S.L. Treatment preference, engagement, and clinical
1322 improvement in pharmacotherapy versus psychotherapy for depression. *Behav Res Ther* **48**,
1323 799-804 (2010).
- 1324 182. Dennis, C.L. & Chung-Lee, L. Postpartum depression help-seeking barriers and maternal
1325 treatment preferences: a qualitative systematic review. *Birth* **33**, 323-31 (2006).
- 1326 183. Cameron, E.E., Hunter, D., Sedov, I.D. & Tomfohr-Madsen, L.M. What do dads want? Treatment
1327 preferences for paternal postpartum depression. *J Affect Disord* **215**, 62-70 (2017).
- 1328 184. de Camps Meschino, D., Philipp, D., Israel, A. & Vigod, S. Maternal-infant mental health:
1329 postpartum group intervention. *Arch Womens Ment Health* **19**, 243-51 (2016).
- 1330 185. Dennis, C.L. & Hodnett, E. Psychosocial and psychological interventions for treating postpartum
1331 depression. *Cochrane Database Syst Rev*, CD006116 (2007).
- 1332 186. Ashford, M.T., Olander, E.K. & Ayers, S. Computer- or web-based interventions for perinatal
1333 mental health: A systematic review. *J Affect Disord* **197**, 134-46 (2016).
- 1334 187. Goodman, J.H., Watson, G.R. & Stubbs, B. Anxiety disorders in postpartum women: A systematic
1335 review and meta-analysis. *J Affect Disord* **203**, 292-331 (2016).
- 1336 188. Challacombe, F.L. et al. A pilot randomized controlled trial of time-intensive cognitive-
1337 behaviour therapy for postpartum obsessive-compulsive disorder: effects on maternal
1338 symptoms, mother-infant interactions and attachment. *Psychol Med* **47**, 1478-1488 (2017).
- 1339 189. Bisson, J.I., Roberts, N.P., Andrew, M., Cooper, R. & Lewis, C. Psychological therapies for chronic
1340 post-traumatic stress disorder (PTSD) in adults. *Cochrane Database Syst Rev*, CD003388
1341 (2013).
- 1342 190. Molyneaux, E., Howard, L.M., McGeown, H.R., Karia, A.M. & Trevillion, K. Antidepressant
1343 treatment for postnatal depression. *Cochrane Database Syst Rev*, CD002018 (2014).

- 1344 191. Milgrom, J. et al. Treatment of postnatal depression with cognitive behavioural therapy,
1345 sertraline and combination therapy: a randomised controlled trial. *Aust N Z J Psychiatry* **49**,
1346 236-45 (2015).
- 1347 192. Lam, R.W. et al. Effects of combined pharmacotherapy and psychotherapy for improving work
1348 functioning in major depressive disorder. *Br J Psychiatry* **203**, 358-65 (2013).
- 1349 193. Lam, R.W. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical
1350 Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease
1351 Burden and Principles of Care. *Can J Psychiatry* **61**, 510-23 (2016).
- 1352 194. Khalifeh, H., Hunt, I.M., Appleby, L. & Howard, L.M. Suicide in perinatal and non-perinatal
1353 women in contact with psychiatric services: 15 year findings from a UK national inquiry.
1354 *Lancet Psychiatry* **3**, 233-42 (2016).
- 1355 195. Orsolini, L. & Bellantuono, C. Serotonin reuptake inhibitors and breastfeeding: a systematic
1356 review. *Hum Psychopharmacol* **30**, 4-20 (2015).
- 1357 196. Sriraman, N.K., Melvin, K. & Meltzer-Brody, S. ABM Clinical Protocol #18: Use of
1358 Antidepressants in Breastfeeding Mothers. *Breastfeed Med* **10**, 290-9 (2015).
- 1359 197. Dennis, C.L., Ross, L.E. & Herxheimer, A. Oestrogens and progestins for preventing and treating
1360 postpartum depression. *Cochrane Database Syst Rev*, CD001690 (2008).
- 1361 198. Deligiannidis, K.M. & Freeman, M.P. Complementary and alternative medicine therapies for
1362 perinatal depression. *Best Pract Res Clin Obstet Gynaecol* **28**, 85-95 (2014).
- 1363 199. Pritchett, R.V., Daley, A.J. & Jolly, K. Does aerobic exercise reduce postpartum depressive
1364 symptoms? a systematic review and meta-analysis. *Br J Gen Pract* **67**, e684-e691 (2017).
- 1365 200. Meltzer-Brody, S. et al. Evaluating the clinical effectiveness of a specialized perinatal psychiatry
1366 inpatient unit. *Arch Womens Ment Health* (2013).
- 1367 201. Glangeaud-Freudenthal, N.M., Howard, L.M. & Sutter-Dallay, A.L. Treatment - mother-infant
1368 inpatient units. *Best Pract Res Clin Obstet Gynaecol* **28**, 147-57 (2014).
- 1369 202. Health, A.G.D.o. (Commonwealth of Australia, 2013).
- 1370 203. Bergink, V. et al. Treatment of psychosis and mania in the postpartum period. *Am J Psychiatry*
1371 **172**, 115-23 (2015).
- 1372 **One of the first papers to present an elegant algorithm for assessment and treatment of**
1373 **postpartum psychosis.**
- 1374 204. Babu, G.N., Thippeswamy, H. & Chandra, P.S. Use of electroconvulsive therapy (ECT) in
1375 postpartum psychosis-a naturalistic prospective study. *Arch Womens Ment Health* **16**, 247-51
1376 (2013).
- 1377 205. Lichtenberg, P., Navon, R., Wertman, E., Dasberg, H. & Lerer, B. Post-partum psychosis in adult
1378 GM2 gangliosidosis. A case report. *Br J Psychiatry* **153**, 387-9 (1988).
- 1379 206. Doucet, S., Jones, I., Letourneau, N., Dennis, C.L. & Blackmore, E.R. Interventions for the
1380 prevention and treatment of postpartum psychosis: a systematic review. *Arch Womens Ment*
1381 *Health* (2010).
- 1382 207. Gobbi, G. Quetiapine in postpartum psychosis. *J Clin Psychopharmacol* **34**, 744-5 (2014).
- 1383 208. Smith, B. & Dubovsky, S.L. Pharmacotherapy of mood disorders and psychosis in pre- and post-
1384 natal women. *Expert Opin Pharmacother* **18**, 1703-1719 (2017).
- 1385 209. Meador, K.J. et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years
1386 (NEAD study): a prospective observational study. *Lancet Neurol* **12**, 244-52 (2013).
- 1387 210. Bromley, R.L., Weston, J. & Marson, A.G. Maternal Use of Antiepileptic Agents During Pregnancy
1388 and Major Congenital Malformations in Children. *JAMA* **318**, 1700-1701 (2017).
- 1389 211. Ornoy, A., Weinstein-Fudim, L. & Ergaz, Z. Antidepressants, Antipsychotics, and Mood
1390 Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with
1391 Depression. *Birth Defects Res* **109**, 933-956 (2017).
- 1392 212. Bogen, D.L., Sit, D., Genovese, A. & Wisner, K.L. Three cases of lithium exposure and exclusive
1393 breastfeeding. *Arch Womens Ment Health* **15**, 69-72 (2012).

- 1394 213. Viguera, A.C. et al. Lithium in breast milk and nursing infants: clinical implications. *Am J*
1395 *Psychiatry* **164**, 342-5 (2007).
- 1396 214. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders
1397 (American Psychiatric Press, Arlington, VA, 2013).
- 1398 215. Kahneman, D. & Deaton, A. High income improves evaluation of life but not emotional well-
1399 being. *Proceedings of the National Academy of Sciences of the United States of America* **107**,
1400 16489-93 (2010).
- 1401 216. Diego, M.A. & al., e. Withdrawn and intrusive maternal interaction style and infant frontal EEG
1402 asymmetry shifts in infants. *Infant Behavior & Development* **29**, 220-229 (2006).
- 1403 217. Reck, C. et al. Interactive regulation of affect in postpartum depressed mothers and their
1404 infants: an overview. *Psychopathology* **37**, 272-80 (2004).
- 1405 218. Murray, L. et al. Controlled trial of the short- and long-term effect of psychological treatment of
1406 post-partum depression: 2. Impact on the mother-child relationship and child outcome. *British*
1407 *Journal of Psychiatry* **182**, 420-7 (2003).
- 1408 219. Field, T.M. Early interactions between infants and their postpartum depressed mothers. *Infant*
1409 *Behavior & Development* (2002).
- 1410 220. Lyons-Ruth, K. Contributions of the Mother-Infant Relationship to Dissociative, Borderline, and
1411 Conduct Symptoms in Young Adulthood. *Infant Ment Health J* **29**, 203-218 (2008).
- 1412 221. Pearson, R.M. et al. Maternal depression during pregnancy and the postnatal period: risks and
1413 possible mechanisms for offspring depression at age 18 years. *JAMA Psychiatry* **70**, 1312-9
1414 (2013).
- 1415 222. Cooper, P.J., De Pascalis, L., Woolgar, M., Romaniuk, H. & Murray, L. Attempting to prevent
1416 postnatal depression by targeting the mother-infant relationship: a randomised controlled
1417 trial. *Prim Health Care Res Dev* **16**, 383-97 (2015).
- 1418 223. Abel, K.M., Webb, R.T., Salmon, M.P., Wan, M.W. & Appleby, L. Prevalence and predictors of
1419 parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and
1420 baby psychiatric care in England. *J Clin Psychiatry* **66**, 781-9; quiz 808-9 (2005).
- 1421 224. Ware, J.E., Jr. & Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I.
1422 Conceptual framework and item selection. *Medical Care* **30**, 473-83 (1992).
- 1423 225. Kalyoncu, U., Dougados, M., Daures, J.P. & Gossec, L. Reporting of patient-reported outcomes in
1424 recent trials in rheumatoid arthritis: a systematic literature review. *Annals of the Rheumatic*
1425 *Diseases* **68**, 183-90 (2009).
- 1426 226. Ware, J., Jr., Kosinski, M. & Keller, S.D. A 12-Item Short-Form Health Survey: construction of
1427 scales and preliminary tests of reliability and validity. *Medical Care* **34**, 220-33 (1996).
- 1428 227. Zubaran, C. & Foresti, K. Investigating quality of life and depressive symptoms in the
1429 postpartum period. *Women and birth : journal of the Australian College of Midwives* **24**, 10-6
1430 (2011).
- 1431 228. Mogos, M.F., August, E.M., Salinas-Miranda, A.A., Sultan, D.H. & Salihu, H.M. A Systematic Review
1432 of Quality of Life Measures in Pregnant and Postpartum Mothers. *Appl Res Qual Life* **8**, 219-250
1433 (2013).
- 1434 229. Symon, A., MacDonald, A. & Ruta, D. Postnatal quality of life assessment: Introducing the
1435 Mother-Generated Index. *Birth: Issues in Perinatal Care* **29**, 40-46 (2002).
- 1436 230. Hill, P.D., Aldag, J.C., Hekel, B., Riner, G. & Bloomfield, P. Maternal Postpartum Quality of Life
1437 Questionnaire. *Journal of Nursing Measurement* **14**, 205-20 (2006).
- 1438 231. Huang, K., Tao, F., Liu, L. & Wu, X. Does delivery mode affect women's postpartum quality of life
1439 in rural China? *Journal of Clinical Nursing* **21**, 1534-43 (2012).
- 1440 232. Ruta, D.A., Garratt, A.M., Leng, M., Russell, I.T. & MacDonald, L.M. A new approach to the
1441 measurement of quality of life. The Patient-Generated Index. *Medical Care* **32**, 1109-26 (1994).
- 1442 233. Brenes, G.A. Anxiety, depression, and quality of life in primary care patients. *Prim Care*
1443 *Companion J Clin Psychiatry* **9**, 437-43 (2007).

- 1444 234. Roberts, J., Lenton, P., Keetharuth, A.D. & Brazier, J. Quality of life impact of mental health
1445 conditions in England: results from the adult psychiatric morbidity surveys. *Health Qual Life*
1446 *Outcomes* **12**, 1477-7525 (2014).
- 1447 235. Barkin, J.L., Wisner, K.L., Bromberger, J.T., Beach, S.R. & Wisniewski, S.R. Assessment of
1448 functioning in new mothers. *Journal of Womens Health* **19**, 1493-9 (2010).
- 1449 236. Sadat, Z., Abedzadeh-Kalahroudi, M., Kafaei Atrian, M., Karimian, Z. & Sooki, Z. The Impact of
1450 Postpartum Depression on Quality of Life in Women After Child's Birth. *Iran Red Crescent Med J*
1451 **16**, 5 (2014).
- 1452 237. Webster, J., Nicholas, C., Velacott, C., Cridland, N. & Fawcett, L. Quality of life and depression
1453 following childbirth: impact of social support. *Midwifery* **27**, 745-9 (2011).
- 1454 238. Bodhare, T.N., Sethi, P., Bele, S.D., Gayatri, D. & Vivekanand, A. Postnatal quality of life,
1455 depressive symptoms, and social support among women in southern India. *Women and Health*
1456 **55**, 353-65 (2015).
- 1457 239. Bauer, A., Parsonage, M., Knapp, M., Iemmi, V. & Adelaja, B. (London School of Economics and
1458 the Centre for Mental Health, London, 2014).
- 1459 240. Vliegen, N., Casalin, S. & Luyten, P. The course of postpartum depression: a review of
1460 longitudinal studies. *Harvard Review of Psychiatry* **22**, 1-22 (2014).
- 1461 241. Dolman, C., Jones, I.R. & Howard, L.M. Women with bipolar disorder and pregnancy: factors
1462 influencing their decision-making. *BJPsych Open* **2**, 294-300 (2016).
- 1463 242. Dolman, C., Jones, I. & Howard, L.M. Pre-conception to parenting: a systematic review and
1464 meta-synthesis of the qualitative literature on motherhood for women with severe mental
1465 illness. *Arch Womens Ment Health* **16**, 173-96 (2013).
- 1466 243. Paulson, J.F. & Bazemore, S.D. Prenatal and postpartum depression in fathers and its
1467 association with maternal depression: a meta-analysis. *JAMA* **303**, 1961-9 (2010).
- 1468 244. Davis, R.N., Davis, M.M., Freed, G.L. & Clark, S.J. Fathers' depression related to positive and
1469 negative parenting behaviors with 1-year-old children. *Pediatrics* **127**, 612-8 (2011).
- 1470 245. Hoffman, C., Dunn, D.M. & Njoroge, W.F.M. Impact of Postpartum Mental Illness Upon Infant
1471 Development. *Curr Psychiatry Rep* **19**, 100 (2017).
- 1472 246. Paulson, J.F., Bazemore, S.D., Goodman, J.H. & Leiferman, J.A. The course and interrelationship
1473 of maternal and paternal perinatal depression. *Archives of Women's Mental Health* **19**, 655-663
1474 (2016).
- 1475 247. Lund, C. et al. Poverty and mental disorders: breaking the cycle in low-income and middle-
1476 income countries. *Lancet* **378**, 1502-14 (2011).
- 1477 248. Allen, J., Balfour, R., Bell, R. & Marmot, M. Social determinants of mental health. *Int Rev*
1478 *Psychiatry* **26**, 392-407 (2014).
- 1479 249. Naila, K. Gender, poverty, and inequality: a brief history of feminist contributions in the field of
1480 international development. *Gender and Development* **23** (2015).
- 1481 250. Burns, P.A., Zunt, J.R., Hernandez, B. Intimate Partner Violence, Poverty, and Maternal Health
1482 Care-Seeking Among Young Women in Kenya: a Cross-Sectional Analysis Informing the New
1483 Sustainable Development Goals. *Global and Social Welfare* (2018).
- 1484 251. WHO, H.W. (World Health Organization, Geneva, 2014) .
- 1485 252. Chisholm, D. et al. Scaling-up treatment of depression and anxiety: a global return on
1486 investment analysis. *Lancet Psychiatry* **3**, 415-24 (2016).
- 1487 253. Chisholm, D., Lund, C. & Saxena, S. Cost of scaling up mental healthcare in low- and middle-
1488 income countries. *Br J Psychiatry* **191**, 528-35 (2007).
- 1489 254. Rahman, A., Surkan, P.J., Cayetano, C.E., Rwagatare, P. & Dickson, K.E. Grand challenges:
1490 integrating maternal mental health into maternal and child health programmes. *PLoS Med* **10**,
1491 e1001442 (2013).
- 1492 255. Patel, V. et al. Addressing the burden of mental, neurological, and substance use disorders: key
1493 messages from Disease Control Priorities, 3rd edition. *Lancet* **387**, 1672-85 (2016).
- 1494 256. Organization, B.o.W.H. (ed. [PDF], d.h.d.d.o.B.) (2013).

257. Rahman, A., Malik, A., Sikander, S., Roberts, C. & Creed, F. Cognitive behaviour therapy-based intervention by community health workers for mothers with depression and their infants in rural Pakistan: a cluster-randomised controlled trial. *Lancet* **372**, 902-9 (2008).
258. Rojas, G. et al. Treatment of postnatal depression in low-income mothers in primary-care clinics in Santiago, Chile: a randomised controlled trial. *Lancet* **370**, 1629-37 (2007).
259. Chibanda, D. et al. Group problem-solving therapy for postnatal depression among HIV-positive and HIV-negative mothers in Zimbabwe. *J Int Assoc Provid AIDS Care* **13**, 335-41 (2014).
260. Jahanfar, S., Howard, L.M. & Medley, N. Interventions for preventing or reducing domestic violence against pregnant women. *Cochrane Database Syst Rev*, CD009414 (2014).
261. Shrestha, S.D., Pradhan, R., Tran, T.D., Gualano, R.C. & Fisher, J.R. Reliability and validity of the Edinburgh Postnatal Depression Scale (EPDS) for detecting perinatal common mental disorders (PCMDs) among women in low-and lower-middle-income countries: a systematic review. *BMC Pregnancy Childbirth* **16**, 72 (2016).

Acknowledgements

We would like to thank Dr. Alan Gemmill from Parent-Infant Research Institute and Holly Krohn from the University of North Carolina at Chapel Hill for their contributions to the preparation of this manuscript.

Author contributions

Introduction (All); Epidemiology (T.M-O.); Mechanisms/pathophysiology (I.J. and S.M-B.); Diagnosis, screening and prevention (L.M.H., S.H. and J.M.); Management (S.V. and V.B.); Quality of life (J.M.); Outlook (All); Overview of Primer (S.M-B.).

Competing interests

S.M-B. has received research grant support to The University of North Carolina at Chapel Hill from Sage Therapeutics and Janssen. L.M.H. is funded through a National Institute for Health Research (NIHR) Professorship in maternal mental health (NIHR-RP-R3-12-011). V.B. is supported by NWO (VENI 91616036 and Clinical Fellowship 90715620) and the EMC fellowship. IJ is a trustee of Action on Postpartum Psychosis and the Maternal Mental Health Alliance and is supported through the National Centre for Mental Health grant from Health and Care Research Wales. All other authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reviewer information

Nature Reviews Disease Primers would like to thank V. Glover, C. Otte, T. Gur and L. Osborne, and the other anonymous reviewer(s), for their contribution to the peer review of this work.

1539 **Display items**

1540

1541 **Box 1. Paternal postpartum depression.**

1542 Fathers can also experience depression after the birth of a child. Indeed, in men, the prevalence of
1543 depression after the birth of a child is greater than at other times during life²⁴³. Although the
1544 literature of paternal depression is much smaller than that for maternal depression, the available
1545 literature demonstrates that paternal depression increases the risk for long-term adverse outcomes
1546 in the child due to potential impairments in parenting^{244, 245}. In addition, a strong link between
1547 maternal depression and paternal depression has been reported. Pregnant women who had
1548 partners with depression during their pregnancy had worse depression symptom severity during
1549 the first six months postpartum²⁴⁶. Thus, including fathers in health assessments during the
1550 postpartum period and screening fathers for postpartum psychiatric disorders at similar time
1551 intervals as maternal screening is important. Efforts aiming to improve the overall health and
1552 functioning of the family unit will lead to best outcomes for the child^{243, 245}.

1553

1554

1555

Box 2. Postpartum mental illness in low-income and middle-income countries

In resource-poor settings, women of reproductive age typically have socio-economic and health challenges that interplay in mutually reinforcing ways.^{247, 248} For example, low levels of education, low gender status, food insecurity, domestic abuse and lack of access to social and health services leave women and girls vulnerable to maternal mortality and chronic morbidities, including common mental health disorders.^{249, 250} Indeed, the prevalence of common perinatal mental disorders in low- and lower-middle-income countries is higher than in high-income countries. One systematic review and meta-analysis²¹ demonstrated a weighted mean prevalence of 15.6% in pregnant women and 19.8% in women after childbirth. The most strongly associated factors for perinatal mental disorders are socio-economic disadvantage, unintended pregnancy, younger age, unmarried status, lacking intimate partner empathy and support, hostile in-laws, partner violence, insufficient emotional and practical support, a history of mental health problems and in certain settings, a female infant.²¹

[H1] Considerations for management

Mental health prevention and treatment investments in high-income countries is more than US\$50 per year per person, compared with less than US\$2 in most LMIC,²⁵¹ resulting in a profound paucity of mental health providers in these settings. The intervention coverage for common mental disorders (including those that occur during the perinatal period) ranges from 7% to 28% in LMICs.²⁵² The low monetary allocation represents, in part, poor appreciation by decision makers of the effect of mental illness on population disability and socio-economic development, low levels of political will and capacity, and competing health and development priorities.²⁵³ Interventions that are most likely to succeed in LMICs would, therefore, need to adopt a systems strengthening, integrated and low-cost approach. Examples showing promise have integrated mental health into primary care, maternal and child health services or into the routine community based delivery of

1581 health services (carried out by trained lay workers, or primary care healthworkers, using a task-
1582 sharing approach)²⁵⁴. Emerging evidence supports the benefit of including poverty alleviation
1583 strategies in to mental health interventions.²⁵⁵

1584

1585 **[H1] Types of interventions**

1586 A systematic review and meta-analysis of evidence of common perinatal mental disorder trials from
1587 LMIC, reported similar relative risk outcomes in studies carried out in high-income countries²⁵⁶. For
1588 the 13 trials selected, the pooled effect size for maternal depression was -0.38. In this review,
1589 trials that demonstrated positive results used several culturally adapted treatment paradigms,
1590 either singly or in combination. The Thinking Health Program in Pakistan was a cognitive behaviour
1591 therapy (CBT) intervention delivered in homes in a semi-rural setting by Lady Health Workers.²⁵⁷
1592 Uptake of the intervention leveraged the belief, within multi-generational households, that the
1593 intervention with the mother would improve the infant's well-being . In an urban, deprived setting in
1594 Chile, midwives and nurses were trained to deliver eight weekly structured psychoeducational
1595 group sessions. These sessions included information about symptoms and treatments, some
1596 problem solving strategies, behavioural activation strategies (such as scheduling pleasurable
1597 activities) and some cognitive techniques using postnatal examples ²⁵⁸ .

1598 Subsequently, a trial in Zimbabwe ²⁵⁹ used peer counsellors to deliver six weeks of group problem
1599 solving therapy adapted for the local setting to postnatal women with depression. In this study,
1600 family members were co-opted to support the mothers through strategies identified in the problem
1601 solving and a specific treatment element that explored community resources and support systems
1602 was included. Six weeks after the intervention, the drop in mean EPDS score was greater in the
1603 PST group than the control group who received antidepressant therapy. No difference in outcomes
1604 between women with or without HIV was reported.

1605

Box 3. Targeting risk factors for postpartum depression.

Assessing the common psychosocial risk factors for postpartum depression might have the following functions:

- Assisting in the initiation of targeted interventions or determining rational management decisions to mitigate the risks across several global settings through
 - risk reduction interventions (for example, referring women for social grants, to domestic violence support groups or to a women's shelter and provision of integrated interventions for the mood disorder, which also addresses domestic violence²⁶⁰
 - activation of protective factors, (such as interpersonal therapy for relationship difficulties or activating social support networks)^{175, 260}.
- Assisting in screening of women who have an increased risk of postpartum depression but do not currently have the disorder.
- Assisting in timely referral for support in women with suspected postpartum depression and complicated psychosocial risk factors who are reluctant to endorse symptoms during screening due to stigma and poor contextual validity of the screening tool in some global settings, among other reasons²⁶¹. This approach acknowledges that there may be several contextual factors contributing to false negative mental health screening results.

Box 4. General management guidelines for non-psychotic psychiatric disorders

1. Identify somatic comorbidities and optimize their management.
2. Check the mode of delivery, if complications were present and if delivery was experienced as traumatic. In the case of post-traumatic stress symptoms, consider specific treatments.
3. Assess for suicidal thoughts and intrusive thoughts of harm toward the baby. Consider the safety of the baby and whether the mother can provide care for the baby if she is alone or if other adult supervision is required.
4. Ask the mother of her attitude towards her baby and observe maternal-child interactions. Consider specific treatments with signs of problematic interactions or bonding.
5. Review the feeding pattern of the baby. Address problems with breast or bottle-feeding.
6. Provide strategies to preserve sleep, such as finding another person to feed the infant at night.
7. Assess psychiatric history before delivery. Review the nature and effectiveness of past treatments, and restart previous effective treatment when appropriate.

1643 **Figure 1, Mechanisms of postpartum psychiatric disorders.**

1644 Several factors have been implicated in the aetiology of postpartum psychiatric disorders, including
1645 both postpartum depression and postpartum psychosis. These factors include psycho-social
1646 factors and biological factors that are specific to pregnancy and the postpartum period, such as
1647 drastic alterations in gonadal sex steroids and impaired mother-infant interactions. Whether the
1648 aetiology of psychiatric disorders occurring in prenatally, during pregnancy or during the
1649 postpartum period is different requires future study.

1650

1651 **Figure 2. Management of first onset postpartum psychiatric disorders.**

1652 Management of postpartum psychiatric disorders should take into account the diagnosis (such as
1653 psychosis, anxiety or depression), symptom severity and, with regards to mood and anxiety
1654 disorders, whether the mother is breastfeeding.

1655

Online only	
Editorial reporting summary	Forthcoming; not currently used
Subject categories	<p>Yes</p> <p>Biological sciences / Neuroscience / Diseases of the nervous system / Depression [URI /631/378/1689/1414]</p> <p>Biological sciences / Neuroscience / Diseases of the nervous system / Anxiety [URI /631/378/1689/1300]</p> <p>Health sciences / Diseases / Psychiatric disorders [URI /692/699/476]</p> <p>Biological sciences / Neuroscience / Diseases of the nervous system / Psychosis [URI /631/378/1689/1761]</p> <p>Health sciences / Health care / Prognosis / Pregnancy outcome [URI /692/700/1750/1747]</p>
Techniques terms	No [Text here]
ToC blurb (40 words max.)	Postpartum psychiatric disorders comprise postpartum depression and anxiety, which are relatively common, and the rare but severe disorder, postpartum psychosis. This Primer by Meltzer-Brody and colleagues reviews the mechanisms underlying the development of postpartum psychiatric disorders, and the approach to diagnosis and treatment of these disorders.
Sensitive images	None
Permissions info for Powerpoint slides	None
Supplementary items (please list no. of boxes, tables etc):	None
No. of animations:	0
Legends for supplementary videos	NA

1656

1657